<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>&lt;h2&gt;HIV, HEPATITIS B AND HEPATITIS C&lt;/h2&gt;
&lt;p&gt;&lt;strong&gt;DMD3 DENT5311&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Dr Jee-Yun Leung&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;BDSc(Hons) MSc(SpecCareDent) DSCD(RCS Eng) DClinDent(SND) MRACDS(SND) FANZASND&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Consultant, Special Needs Dentistry | Fiona Stanley Fremantle Hospital Group&lt;/p&gt;
&lt;p&gt;Senior Lecturer | The University of Western Australia&lt;/p&gt;</text>
    <formatted_text>**DMD3 DENT5311**

**Dr Jee-Yun Leung**

*BDSc(Hons) MSc(SpecCareDent) DSCD(RCS Eng) DClinDent(SND) MRACDS(SND) FANZASND*

Consultant, Special Needs Dentistry | Fiona Stanley Fremantle Hospital Group

Senior Lecturer | The University of Western Australia</formatted_text>
  </page>
  <page number="2">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;b&gt;LEARNING OUTCOMES&lt;/b&gt;
&lt;/div&gt;

*   1. Outline key clinical features and disease progression of blood-borne viruses (HIV, Hepatitis B, Hepatitis C)
*   2. Appreciate the epidemiology of BBVs over time
*   3. Understand the evolution of BBV treatment over time
*   4. Describe BBV-related oral disease, and side-effects of medications
*   5. Understand BBV-transmission, risks and infection control
*   6. Discuss professional obligations under the Australian national guidelines for the management of healthcare workers living with BBV and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses</text>
    <formatted_text>1. Outline key clinical features and disease progression of blood-borne viruses (HIV, Hepatitis B, Hepatitis C)
2. Appreciate the epidemiology of BBVs over time
3. Understand the evolution of BBV treatment over time
4. Describe BBV-related oral disease, and side-effects of medications
5. Understand BBV-transmission, risks and infection control
6. Discuss professional obligations under the Australian national guidelines for the management of healthcare workers living with BBV and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses</formatted_text>
  </page>
  <page number="3">
    <text/>
  </page>
  <page number="4">
    <text>&lt;h2&gt;HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME&lt;/h2&gt;

*   **HIV Infection:** Infection with human immunodeficiency virus (HIV), a retrovirus, causes HIV disease and ultimately damages certain T lymphocytes, producing the acquired immune deficiency syndrome (AIDS).
*   **AIDS** is a lethal infection, and the final and most advanced stage of infection caused by HIV. Defined as [1] HIV infection plus [2] one or more AIDS-defining (opportunistic) illnesses, and [3] a CD4 T-lymphocyte count &lt;200 × 106/L (or a CD4+ T-cell percentage of total lymphocytes of &lt;14%)

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;2&quot;&gt;Box 3.13 Some AIDS-defining illnesses&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;b&gt;Fungi&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;• Candidosis: oesophageal • &lt;i&gt;Pneumocystis jiroveci&lt;/i&gt; pneumonia&lt;br&gt;• Cryptococcosis • Histoplasmosis&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;b&gt;Viruses&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;• Herpes simplex: chronic ulcers for more than a month&lt;br&gt;• Cytomegalovirus disease&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;b&gt;Parasites&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;• Toxoplasmosis&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;b&gt;Mycobacteria&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;• Tuberculosis: disseminated or extrapulmonary • Atypical mycobacterioses&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;b&gt;Tumours&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;• Kaposi's sarcoma (HHV-8) • Lymphoma (EBV) • Cervical carcinoma (HPV)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;b&gt;Encephalopathy&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;• HIV-related&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>- **HIV Infection:** Infection with human immunodeficiency virus (HIV), a retrovirus, causes HIV disease and ultimately damages certain T lymphocytes, producing the acquired immune deficiency syndrome (AIDS).
- **AIDS** is a lethal infection, and the final and most advanced stage of infection caused by HIV. Defined as [1] HIV infection plus [2] one or more AIDS-defining (opportunistic) illnesses, and [3] a CD4 T-lymphocyte count &lt;200 × 10⁶/L (or a CD4+ T-cell percentage of total lymphocytes of &lt;14%)

#### Some AIDS-Defining Illnesses

| Category | Illnesses |
| :--- | :--- |
| Fungi | Candidosis: oesophageal; *Pneumocystis jiroveci* pneumonia; Cryptococcosis; Histoplasmosis |
| Viruses | Herpes simplex: chronic ulcers for more than a month; Cytomegalovirus disease |
| Parasites | Toxoplasmosis |
| Mycobacteria | Tuberculosis: disseminated or extrapulmonary; Atypical mycobacterioses |
| Tumours | Kaposi's sarcoma (HHV-8); Lymphoma (EBV); Cervical carcinoma (HPV) |
| Encephalopathy | HIV-related |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:00:42" confidence="6" anchor="- **AIDS** is a lethal infection, and the final and most advanced stage of infec">

&gt; [!note] Lecturer — AIDS Definition
&gt; AIDS may be defined by HIV infection with an AIDS-defining illness, a CD4 count below 200 × 10⁶/L, or a CD4 percentage below 14% of total lymphocytes.
</insert>
    </audio_inserts>
  </page>
  <page number="5">
    <text>HUMAN IMMUNODEFICIENCY VIRUS AND
ACQUIRED IMMUNODEFICIENCY SYNDROME

• Two main types of HIV:
   • **HIV-1** = most common. Prevalent throughout the world and responsible for the global HIV pandemic
   • **HIV-2** = geographic distribution much more limited, found primarily in West Africa. Less transmissible, slower disease progression
• Both infect cells expressing &lt;u&gt;CD4 surface receptors&lt;/u&gt;, mainly the &lt;u&gt;T-helper lymphocytes&lt;/u&gt;, and replicate within them, damaging them.</text>
    <formatted_text>- Two main types of HIV:
  - **HIV-1** = most common. Prevalent throughout the world and responsible for the global HIV pandemic
  - **HIV-2** = geographic distribution much more limited, found primarily in West Africa. Less transmissible, slower disease progression
- Both infect cells expressing CD4 surface receptors, mainly the T-helper lymphocytes, and replicate within them, damaging them.</formatted_text>
  </page>
  <page number="6">
    <text>HUMAN IMMUNODEFICIENCY VIRUS AND
ACQUIRED IMMUNODEFICIENCY SYNDROME

• Based on clinical features patients are distributed in three categories:
• A: asymptomatic, acute infection or persistent generalised lymphadenopathy: &gt;500 × 10⁶/L
• B: symptomatic, no acute or chronic conditions: 200–500 × 10⁶/L
• C: AIDS-defining illnesses: &lt; 200 × 10⁶/L
• → vulnerable to opportunistic infections

Australian Centre for Disease Control
Australian Immunisation Handbook

| Level of immunocompromise | Infants aged &lt;12 months, CD4⁺ count | Children aged 1–5 years, CD4⁺ count | Adults and children aged ≥6 years, CD4⁺ count |
| :--- | :--- | :--- | :--- |
| Not immunocompromised | ≥1500 cells/µL | ≥1000 cells/µL | ≥500 cells/µL |
| Moderately immunocompromised | 750–1499 cells/µL | 500–999 cells/µL | 200–499 cells/µL |
| Severely immunocompromised | &lt;750 cells/µL | &lt;500 cells/µL | &lt;200 cells/µL |

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_68768934655083a8.webp)</text>
    <formatted_text>#### Clinical Categories Based on CD4 Count

- Patients are distributed in three categories based on clinical features:
  - **A:** asymptomatic, acute infection or persistent generalised lymphadenopathy: &gt;500 × 10⁶/L
  - **B:** symptomatic, no acute or chronic conditions: 200–500 × 10⁶/L
  - **C:** AIDS-defining illnesses: &lt;200 × 10⁶/L
  - → vulnerable to opportunistic infections

#### Level of Immunocompromise

*Australian Centre for Disease Control — Australian Immunisation Handbook*

| Level of immunocompromise | Infants aged &lt;12 months, CD4⁺ count | Children aged 1–5 years, CD4⁺ count | Adults and children aged ≥6 years, CD4⁺ count |
| :--- | :--- | :--- | :--- |
| Not immunocompromised | ≥1500 cells/µL | ≥1000 cells/µL | ≥500 cells/µL |
| Moderately immunocompromised | 750–1499 cells/µL | 500–999 cells/µL | 200–499 cells/µL |
| Severely immunocompromised | &lt;750 cells/µL | &lt;500 cells/µL | &lt;200 cells/µL |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:24:56" confidence="10" anchor="Severely immunocompromised | &lt;750 cells/µL | &lt;500 cells/µL | &lt;200 cells/µL">

&gt; [!note] Lecturer — CD4 Interpretation
&gt; CD4 counts below 500 indicate immunocompromise, while counts below 200 indicate advanced HIV infection or AIDS.
&gt;
&gt; - An absolute neutrophil count below 1 was described as indicating increased immunocompromise.
&gt; - The trend in CD4 results is more informative than a single count because levels may fluctuate with other infections, dietary factors, time of day, and recent exercise.
&gt; - Unexpectedly high or low results should be checked with a second test where possible, and the CD4 percentage may provide a more stable indication of immune-system changes.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="52,592,944,808" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_68768934655083a8.webp">
        <description>A table categorizing the level of immunocompromise (Not, Moderately, Severely) based on CD4+ cell count thresholds for three specific age groups: infants &lt;12 months, children 1–5 years, and adults/children ≥6 years.</description>
      </img>
    </images>
  </page>
  <page number="7">
    <text>HUMAN IMMUNODEFICIENCY VIRUS AND
ACQUIRED IMMUNODEFICIENCY SYNDROME

The various stages of untreated HIV infection depicting the development of
different opportunistic infections with advanced immunodeficiency.

CD4 lymphocyte count (cells/mm³)
1200
1100
1000
900
800
700
600
500
400
300
200
100
0

Primary
Infection

Acute HIV syndrome

Fever
Myalgia
Rash
Pharyngitis
Adenopathy
Mouth ulcers

Asymptomatic
Thrombocytopenia

weeks
0   3   6   9   12

Minor infections
Skin conditions
Fever
Weight loss
TB
Pneumonia

years
1   2   3   4   5   6   7   8   9   10   11

Toxoplasmosis
Cryptosporidiosis
Lymphoma (NHL)

PJP, KS

MAC, CMV

HIV RNA copies per mL plasma
10⁷
10⁶
10⁵
10⁴
10³
10²

mac: mycobacterium avium complex, cmv: cytomegalovirus, ks: kaposi sarcoma, pjp: pneumocystis jirovecii pneumonia, tb: tuberculosis

CD4+ Lymphocyte Count (Blue Line)
HIV RNA copies (Red Line)

• If untreated, progression to AIDS, occurs a **median of 10 years** after initial infection with HIV
• Moderately immunocompromised = **CD4 count &lt;500/µL**
• Severely immunocompromised (AIDS) = **CD4 count &lt;200/µL**

![The various stages of untreated HIV infection depicting the development of different opportunistic infections with advanced immunodeficiency.](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_62fbfb60bf27834e.webp)</text>
    <formatted_text>The various stages of untreated HIV infection depicting the development of different opportunistic infections with advanced immunodeficiency.

#### Stages of Untreated HIV Infection (Figure)

- **Axes:** CD4 lymphocyte count (cells/mm³) 0–1200 (blue line); HIV RNA copies per mL plasma 10²–10⁷ (red line); timeline in weeks (0–12) then years (1–11)
- **Primary infection:** acute HIV syndrome — fever, myalgia, rash, pharyngitis, adenopathy, mouth ulcers
- **Asymptomatic phase:** thrombocytopenia
- **Progressive phase:** minor infections, skin conditions, fever, weight loss, TB, pneumonia
- **Advanced immunodeficiency:** PJP, KS; toxoplasmosis, cryptosporidiosis, lymphoma (NHL); MAC, CMV

*Abbreviations: MAC — mycobacterium avium complex; CMV — cytomegalovirus; KS — Kaposi sarcoma; PJP — pneumocystis jirovecii pneumonia; TB — tuberculosis*

&gt; If untreated, progression to AIDS occurs a **median of 10 years** after initial infection with HIV.

- Moderately immunocompromised = **CD4 count &lt;500/µL**
- Severely immunocompromised (AIDS) = **CD4 count &lt;200/µL**</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:03:34" confidence="13" anchor="*Abbreviations: MAC — mycobacterium avium complex; CMV — cytomegalovirus; KS — K">

&gt; [!note] Lecturer — HIV Disease Stages
&gt; The early course includes a window period followed by seroconversion illness and then a prolonged asymptomatic period.
&gt;
&gt; - During the initial window period, which lasts several weeks or months, HIV antibodies are initially undetectable.
&gt; - Seroconversion illness occurs approximately two to six weeks after infection and may resemble mononucleosis or influenza; the CD4 count drops, HIV antibodies and HIV-specific cytotoxic T cells become detectable, and peak viral load corresponds with illness severity.
&gt; - After acute illness resolves, the immune response lowers the viral load and raises the CD4 count, but the virus is not cleared and the CD4 count does not return to its pre-infection level.
&gt; - The clinical asymptomatic period lasts approximately two to ten years, with a gradual CD4 decline of about 80 cells/µL per year; symptoms such as weight loss and increasing infections begin as the count falls below 500 cells/µL.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="31,374,689,726" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_62fbfb60bf27834e.webp" caption="The various stages of untreated HIV infection depicting the development of different opportunistic infections with advanced immunodeficiency.">
        <description>This dual-axis line chart illustrates the progression of untreated HIV infection over time, plotting CD4 lymphocyte count (blue line) and HIV RNA viral load (red line). The graph tracks the timeline from primary infection through acute HIV syndrome, a long asymptomatic period, and finally to advanced immunodeficiency (AIDS), marking the onset of specific opportunistic infections such as Tuberculosis (TB), Pneumocystis jirovecii pneumonia (PJP), Kaposi sarcoma (KS), and Mycobacterium avium complex (MAC) at corresponding stages.</description>
      </img>
    </images>
  </page>
  <page number="8">
    <text>HIV – COMORBID CONDITIONS

• HIV/AIDS-defining cancers
  • Common
    • Kaposi sarcoma (can occur orally)
    • Non-Hodgkin lymphoma (can occur orally)
  • Cervical cancer
  • Less common
    • HPV oropharyngeal cancers, liver, lung, colon, recumt, anus, testes, skin

Diffuse large B-cell lymphoma (NHL)

Corti, M., Villafañe, M.F., Solari, R. et al. Non-Hodgkin Lymphomas of the Oral Cavity in AIDS Patients in a Reference Hospital of Infectious Diseases in Argentina: Report of Eleven Cases and Review of the Literature. J Gastrointest Canc 42, 143–148 (2011).

![Diffuse large B-cell lymphoma (NHL) Corti, M., Villafañe, M.F., Solari, R. et al. Non-Hodgkin Lymphomas of the Oral Cavity in AIDS Patients in a Reference Hospital of Infectious Diseases in Argentina: Report of Eleven Cases and Review of the Literature. J Gastrointest Canc 42, 143–148 (2011).](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_1d5cf14a55b2a454.webp)</text>
    <formatted_text>#### HIV/AIDS-Defining Cancers

- **Common:**
  - Kaposi sarcoma (can occur orally)
  - Non-Hodgkin lymphoma (can occur orally)
  - Cervical cancer
- **Less common:**
  - HPV oropharyngeal cancers, liver, lung, colon, rectum, anus, testes, skin

Diffuse large B-cell lymphoma (NHL)

*Corti, M., Villafañe, M.F., Solari, R. et al. Non-Hodgkin Lymphomas of the Oral Cavity in AIDS Patients in a Reference Hospital of Infectious Diseases in Argentina: Report of Eleven Cases and Review of the Literature. J Gastrointest Canc 42, 143–148 (2011).*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:04:47" confidence="12" anchor="- HPV oropharyngeal cancers, liver, lung, colon, rectum, anus, testes, skin">

&gt; [!note] Lecturer — Cancer Risk
&gt; Immunodeficiency compromises immune surveillance, making the immune system less able to identify and destroy damaged or altered cells. This increases the risk of developing cancers associated with HIV, including oropharyngeal, liver, lung, colorectal, anal, testicular, and skin cancers.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="662,411,921,662" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_1d5cf14a55b2a454.webp" caption="Diffuse large B-cell lymphoma (NHL) Corti, M., Villafañe, M.F., Solari, R. et al. Non-Hodgkin Lymphomas of the Oral Cavity in AIDS Patients in a Reference Hospital of Infectious Diseases in Argentina: Report of Eleven Cases and Review of the Literature. J Gastrointest Canc 42, 143–148 (2011).">
        <description>Clinical photo showing a large, reddish-purple, lobulated mass protruding from the oral cavity of a bearded patient. The lesion appears vascular and swollen, displacing the surrounding tissue and obscuring the teeth.</description>
      </img>
    </images>
  </page>
  <page number="9">
    <text>&lt;div style=&quot;border: 2px solid black; padding: 10px; text-align: center; margin-bottom: 20px;&quot;&gt;
&lt;b&gt;HIV – COMORBID CONDITIONS&lt;/b&gt;
&lt;/div&gt;

*   HIV-associated neurocognitive disorders (HAND)
    *   3-level spectrum of cognitive, motor and/or mood problems
        1.  Asymptomatic neurocognitive impairment (ANI)
        2.  Mild neurocognitive disorder (MND)
        3.  HIV-Associated dementia (HAD)

*   Cardiovascular disease (~50% increased risk)

*   Haematological disease: anaemia, thromobocytopenia, neutropenia

*   Opportunistic or co-infections</text>
    <formatted_text>- HIV-associated neurocognitive disorders (HAND)
  - 3-level spectrum of cognitive, motor and/or mood problems
    1. Asymptomatic neurocognitive impairment (ANI)
    2. Mild neurocognitive disorder (MND)
    3. HIV-Associated dementia (HAD)
- Cardiovascular disease (~50% increased risk)
- Haematological disease: anaemia, thrombocytopenia, neutropenia
- Opportunistic or co-infections</formatted_text>
  </page>
  <page number="10">
    <text>VIRAL HEPATITIS

*   **Hepatitis:** term for liver inflammation, and can result form a wide range of insults, from infections to drugs and poisons.
    *   Features: jaundice, pale/fatty faces, itching, nausea, fatigue, weight loss, bleeding tendency, upper abdominal discomfort, fever

*   **Viral hepatitis:** In healthcare, refers to infection by hepatitis B, C or D, which are transmitted parenterally.
    *   Hepatitis B and C are the most relevant to health care, since delivery of health care has the potential to transmit viral hepatitis to both HCWs and patients.

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_8c298dc68bcff7a2.webp)
![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_4ff6fc92dd578930.webp)</text>
    <formatted_text>- **Hepatitis:** term for liver inflammation, and can result from a wide range of insults, from infections to drugs and poisons.
  - Features: jaundice, pale/fatty faeces, itching, nausea, fatigue, weight loss, bleeding tendency, upper abdominal discomfort, fever

- **Viral hepatitis:** in healthcare, refers to infection by hepatitis B, C or D, which are transmitted parenterally.
  - Hepatitis B and C are the most relevant to health care, since delivery of health care has the potential to transmit viral hepatitis to both HCWs and patients.</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:05:47" confidence="7" anchor="- **Hepatitis:** term for liver inflammation, and can result from a wide range o">

&gt; [!note] Lecturer — Hepatitis Effects
&gt; Hepatitis can also cause anorexia, vomiting and malabsorption.
&gt;
&gt; - Jaundice may occur when bilirubin is not properly conjugated or excreted, including because of biliary obstruction.
&gt; - Bile salts may accumulate in the blood and cause itchiness.
&gt; - Reduced bile salt delivery to the intestines can cause malabsorption of fats and fat-soluble vitamins.
</insert>
      <insert timestamp="00:05:56" confidence="4" anchor="- **Hepatitis B and C are the most relevant to health care, since delivery of he">
    - ==Hepatitis D may occur as a co-infection with hepatitis B and is transmitted parenterally.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="785,363,947,668" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_8c298dc68bcff7a2.webp">
        <description>Clinical photo of an elderly male face exhibiting significant yellow discoloration of the skin and sclera, illustrating jaundice.</description>
      </img>
      <img order="1" bbox="784,708,948,789" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_4ff6fc92dd578930.webp">
        <description>Clinical photo: A close-up view of a human eye exhibiting distinct yellowing of the sclera (the white part of the eye). This visual presentation illustrates jaundice, a key feature of liver inflammation mentioned in the slide text.</description>
      </img>
    </images>
  </page>
  <page number="11">
    <text>&lt;h2 style=&quot;text-align: center; border: 2px solid black; padding: 10px;&quot;&gt;HEPATITIS B&lt;/h2&gt;

*   **Definition:** Inflammation of the liver caused by the parenteral infection with hepatitis B virus.
*   The virus is spread through blood contact, and can spread from infected mother to child during birth.

*   **Prognosis:** Depends on age when come into contact with hepatitis B. Can get an acute or chronic illness
    *   Acute: may feel symptomatic for a short time, then recover. Some with acute hepatitis B naturally clear the virus.
    *   Chronic: have virus for life. May not feel unwell, but over time can damage the liver. 6 month wait to find out whether acute hepatitis B becomes chronic.

| Age (when you first come into contact with the virus) | Acute hepatitis B | Chronic hepatitis B |
| :--- | :--- | :--- |
| Infants under one year old | Most will not get any acute hep B signs | 90% will get chronic hepatitis B if not given injection at birth and vaccinations |
| Children aged one to six years old | Most will not get any acute hepatitis B signs | 30% will get chronic hepatitis B |
| Adults or children over six years old | Many will get acute hepatitis B signs | Less than 5% will get chronic hepatitis B |

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_6cdd3ab1841a5de6.webp)
![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_2a3f862cd446a9d1.webp)</text>
    <formatted_text>- **Definition:** inflammation of the liver caused by the parenteral infection with hepatitis B virus.
- The virus is spread through blood contact, and can spread from infected mother to child during birth.

#### Prognosis

Depends on age when coming into contact with hepatitis B. Can get an acute or chronic illness:

- **Acute:** may feel symptomatic for a short time, then recover. Some with acute hepatitis B naturally clear the virus.
- **Chronic:** have virus for life. May not feel unwell, but over time can damage the liver. 6 month wait to find out whether acute hepatitis B becomes chronic.

| Age (when you first come into contact with the virus) | Acute hepatitis B | Chronic hepatitis B |
| :--- | :--- | :--- |
| Infants under one year old | Most will not get any acute hep B signs | 90% will get chronic hepatitis B if not given injection at birth and vaccinations |
| Children aged one to six years old | Most will not get any acute hepatitis B signs | 30% will get chronic hepatitis B |
| Adults or children over six years old | Many will get acute hepatitis B signs | Less than 5% will get chronic hepatitis B |</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:09:34" confidence="3" anchor="- The virus is spread through blood contact, and can spread from infected mother">
    - ==Hepatitis B can also be transmitted through sexual contact.==</insert>
      <insert timestamp="00:15:59" confidence="22" anchor="- **Chronic:** have virus for life. May not feel unwell, but over time can damag">

&gt; [!note] Lecturer — Hepatitis B Treatment
&gt; Many people with chronic hepatitis B have no signs of liver damage and may not require medication.
&gt;
&gt; - Liver check-ups every six to twelve months are important to monitor for liver damage.
&gt; - If liver damage develops, medications may be considered.
&gt; - There is no complete cure because the virus hides inside the nucleus of human liver cells and creates a stable genetic reservoir called covalently closed circular DNA, or cccDNA.
&gt; - Current medications can control viral replication but cannot reach or destroy this reservoir, so treatment suppresses the virus rather than clearing the infection.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="537,322,948,544" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_6cdd3ab1841a5de6.webp">
        <description>A flowchart illustrating the progression and outcomes of acute Hepatitis B infection, showing percentage probabilities for developing subclinical disease, acute hepatitis, carrier state, or chronic hepatitis. The diagram maps subsequent pathways from these states to recovery, fulminant hepatitis, cirrhosis, hepatocellular carcinoma, and death.</description>
      </img>
      <img order="1" bbox="557,653,946,837" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_2a3f862cd446a9d1.webp">
        <description>A data table comparing the likelihood of acute versus chronic Hepatitis B outcomes across three age groups: infants under one year, children aged one to six years, and adults or children over six years. The rows detail specific percentages for developing chronic hepatitis B (ranging from 90% in infants to less than 5% in older individuals) alongside descriptions of acute symptom presentation.</description>
      </img>
    </images>
  </page>
  <page number="12">
    <text>&lt;h2&gt;HEPATITIS B&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;CLINICAL FEATURES&lt;/th&gt;
    &lt;th&gt;EXTRA-HEPATIC CLINICAL FEATURES&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Malaise&lt;/li&gt;
        &lt;li&gt;Weight loss&lt;/li&gt;
        &lt;li&gt;Fatigue&lt;/li&gt;
        &lt;li&gt;Upper abdominal discomfort&lt;/li&gt;
        &lt;li&gt;Jaundice&lt;/li&gt;
        &lt;li&gt;Pale/fatty faeces&lt;/li&gt;
        &lt;li&gt;Bleeding tendency&lt;/li&gt;
        &lt;li&gt;*Chronic liver disease in 5%&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Serum sickness-like syndrome&lt;/li&gt;
        &lt;li&gt;Polyarteritis nodosa&lt;/li&gt;
        &lt;li&gt;Glomerulonephritis&lt;/li&gt;
        &lt;li&gt;Polyarthritis&lt;/li&gt;
        &lt;li&gt;Non-Hodgkin lymphoma&lt;/li&gt;
        &lt;li&gt;Cryoglobulinemic vasculitis&lt;/li&gt;
        &lt;li&gt;Dermatological signs: Gianotti-Crosti syndrome (papular acrodermatitis), urticaria&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>| Clinical features | Extra-hepatic clinical features |
| :--- | :--- |
| Malaise; weight loss; fatigue; upper abdominal discomfort; jaundice; pale/fatty faeces; bleeding tendency; *chronic liver disease in 5% | Serum sickness-like syndrome; polyarteritis nodosa; glomerulonephritis; polyarthritis; non-Hodgkin lymphoma; cryoglobulinemic vasculitis; dermatological signs: Gianotti-Crosti syndrome (papular acrodermatitis), urticaria |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:07:04" confidence="6" anchor="| Malaise; weight loss; fatigue; upper abdominal discomfort; jaundice; pale/fatt">
- ==Bleeding tendency occurs because the liver produces clotting factors.==</insert>
    </audio_inserts>
  </page>
  <page number="13">
    <text>HEPATITIS C

• **Definition:** Inflammation of the liver caused by the parenteral infection with hepatitis C virus. The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious, lifelong illness including slow progressive liver cirrhosis and cancer.

• **Prognosis:** Long-term impact of infection is highly variable (without treatment)
    • 15-25% will spontaneously clear virus without treatment
    • 75-85% will develop chronic hepatitis C infection (10-20% develop liver cirrhosis, 2-5% hepatocellular carcinoma)

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_7ca0356d1d231bc6.webp)</text>
    <formatted_text>- **Definition:** Inflammation of the liver caused by the parenteral infection with hepatitis C virus. The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious, lifelong illness including slow progressive liver cirrhosis and cancer.

- **Prognosis:** Long-term impact of infection is highly variable (without treatment)
  - 15-25% will spontaneously clear virus without treatment
  - 75-85% will develop chronic hepatitis C infection (10-20% develop liver cirrhosis, 2-5% hepatocellular carcinoma)</formatted_text>
    <images>
      <img order="0" bbox="207,593,793,832" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_7ca0356d1d231bc6.webp">
        <description>Flowchart illustrating the natural history and prognosis of Hepatitis C infection, starting from acute infection. It maps the progression rates through resolution, chronic hepatitis, cirrhosis, hepatocellular carcinoma, and death.</description>
      </img>
    </images>
  </page>
  <page number="14">
    <text>&lt;h2&gt;HEPATITIS C&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;CLINICAL FEATURES&lt;/th&gt;
    &lt;th&gt;EXTRA-HEPATIC CLINICAL FEATURES&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Malaise&lt;/td&gt;
    &lt;td&gt;Aplastic anaemia&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Weight loss&lt;/td&gt;
    &lt;td&gt;Thyroid disease&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Fatigue&lt;/td&gt;
    &lt;td&gt;Polyarteritis nodosa&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Upper abdominal discomfort&lt;/td&gt;
    &lt;td&gt;Glomerulonephritis&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Jaundice&lt;/td&gt;
    &lt;td&gt;Peripheral neuropathy&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Pale/fatty faeces&lt;/td&gt;
    &lt;td&gt;Autoimmune disease&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Bleeding tendency&lt;/td&gt;
    &lt;td&gt;Sialadenitis&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;*Chronic liver disease in &amp;gt;70%&lt;/td&gt;
    &lt;td&gt;Liver cancer&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>#### Clinical Features

- Malaise
- Weight loss
- Fatigue
- Upper abdominal discomfort
- Jaundice
- Pale/fatty faeces
- Bleeding tendency
- Chronic liver disease in &gt;70%

#### Extra-Hepatic Clinical Features

- Aplastic anaemia
- Thyroid disease
- Polyarteritis nodosa
- Glomerulonephritis
- Peripheral neuropathy
- Autoimmune disease
- Sialadenitis
- Liver cancer</formatted_text>
  </page>
  <page number="15">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;h2&gt;LIVER CIRRHOSIS&lt;/h2&gt;
&lt;/div&gt;

*   *See GIT/Hepatology lecture*
*   **Compensated liver cirrhosis** = stable phase of the disease, with good long-term prognosis if the cause of cirrhosis is treated.
*   **Decompensated liver cirrhosis** =
    *   associated with high mortality
    *   defined clinically by the presence of complications: ascites, hepatic encephalopathy, variceal haemorrhage or nonobstructive jaundice.
*   Patients may move between decompensated and compensated disease states, depending on response to treatments, acute events and disease progression.
*   **Liver failure (end-stage cirrhosis)** = impairment of the synthetic or metabolic functions of the liver.</text>
    <formatted_text>- *See GIT/Hepatology lecture*
- **Compensated liver cirrhosis** = stable phase of the disease, with good long-term prognosis if the cause of cirrhosis is treated.
- **Decompensated liver cirrhosis** =
  - associated with high mortality
  - defined clinically by the presence of complications: ascites, hepatic encephalopathy, variceal haemorrhage or nonobstructive jaundice.
- Patients may move between decompensated and compensated disease states, depending on response to treatments, acute events and disease progression.
- **Liver failure (end-stage cirrhosis)** = impairment of the synthetic or metabolic functions of the liver.</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:08:26" confidence="5" anchor="**Compensated liver cirrhosis** = stable phase of the disease, with good long-te">
- ==Both hepatitis B and hepatitis C can eventually lead to liver cirrhosis.==</insert>
      <insert timestamp="00:08:54" confidence="6" anchor="**Liver failure (end-stage cirrhosis)** = impairment of the synthetic or metabol">
- ==Dental treatment carries significant risks in patients with decompensated cirrhosis.==</insert>
    </audio_inserts>
  </page>
  <page number="16">
    <text/>
  </page>
  <page number="17">
    <text>&lt;div style=&quot;text-align: center; border: 1px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
MODES OF TRANSMISSION AND&lt;br&gt;
AT-RISK POPULATIONS
&lt;/div&gt;

*   **HIV** = blood, semen / vaginal /rectal fluids (sexual contact)
    *   Injecting drug use
    *   Vertically from mother to child
    *   Men who have sex with men

*   **Hep B** = blood, semen / vagina / rectal fluids (sexual contact).
    *   Vertical transmission from mother to child at birth

*   **Hep C** = blood
    *   Strongly associated with risky injecting behaviour
    *   Blood transfusion or transplant, or blood product for clotting disorder, before 1993 (Hep C)
    *   Long-term renal dialysis</text>
    <formatted_text>- **HIV** = blood, semen / vaginal / rectal fluids (sexual contact)
  - Injecting drug use
  - Vertically from mother to child
  - Men who have sex with men

- **Hep B** = blood, semen / vaginal / rectal fluids (sexual contact)
  - Vertical transmission from mother to child at birth

- **Hep C** = blood
  - Strongly associated with risky injecting behaviour
  - Blood transfusion or transplant, or blood product for clotting disorder, before 1993 (Hep C)
  - Long-term renal dialysis</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:09:56" confidence="3" anchor="Long-term renal dialysis">
- ==Screening had not yet been introduced before 1993.==</insert>
    </audio_inserts>
  </page>
  <page number="18">
    <text>EPIDEMIOLOGY

Australian
Centre for
Disease
Control

Home Our work Outbreaks Diseases and surveillance Statements and advice Pu

Home &gt; Diseases and surveillance &gt; Surveillance systems and networks

National Notifiable Diseases
Surveillance System (NNDSS)

The NNDSS coordinates data on more than 70 diseases that
present a risk to public health in Australia. This helps us identify
trends in diseases, assess the impact of disease control programs
and develop evidence-informed advice to reduce the impact of
these diseases.

AUSTRALIA

National Health Security (National Notifiable Disease List) Instrument 2018
made under section 11 of the
*National Health Security Act 2007*

Compilation No. 7

Compilation date: 22 May 2026
Includes amendments: F2026L00611
About this compilation

UNSW
Kirby Institute</text>
    <formatted_text>#### Australian Centre for Disease Control

Home &gt; Diseases and surveillance &gt; Surveillance systems and networks

#### National Notifiable Diseases Surveillance System (NNDSS)

The NNDSS coordinates data on more than 70 diseases that present a risk to public health in Australia. This helps us identify trends in diseases, assess the impact of disease control programs and develop evidence-informed advice to reduce the impact of these diseases.

#### National Health Security (National Notifiable Disease List) Instrument 2018

Made under section 11 of the *National Health Security Act 2007*

- Compilation No. 7
- Compilation date: 22 May 2026
- Includes amendments: F2026L00611

UNSW Kirby Institute</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:10:20" confidence="12" anchor="The NNDSS coordinates data on more than 70 diseases that present a risk to publi">

&gt; [!note] Lecturer — Surveillance Methods
&gt; Australian infectious-disease epidemiology is monitored through several complementary data sources.
&gt;
&gt; - Case reporting, behavioural surveys, biological surveys and clinical data collection are used.
&gt; - The Kirby Institute at the University of New South Wales coordinates national surveillance and reporting for HIV, viral hepatitis and sexually transmissible infections on behalf of the Australian Government.
</insert>
    </audio_inserts>
  </page>
  <page number="19">
    <text>HIV/AIDS

400
350
300
250
200
150
100
50
0
Number of notifications

1200
1000
800
600
400
200
0
National notifications

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

QLD NSW VIC WA National

![Figure 1: HIV notifications by jurisdiction, 2013 – 2022](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_5abf3f6f38302b5a.webp)</text>
    <formatted_text>#### HIV/AIDS

- Left chart: Number of notifications (y-axis 0–400, increments of 50)
- Right chart: National notifications (y-axis 0–1200, increments of 200)
- X-axis (both charts): 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022
- Series: QLD, NSW, VIC, WA, National</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:11:25" confidence="9" anchor="X-axis (both charts): 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022">
- ==HIV diagnoses in Australia have halved over the last decade.==
- ==New diagnoses have fallen significantly since 2014.==
- Increased HIV testing, treatment as prevention, improved treatment adherence, post-exposure prophylaxis and pre-exposure prophylaxis contributed to the decline.
- When viral load is undetectable through effective treatment, the risk of transmission was described as zero.</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="278,458,734,774" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_5abf3f6f38302b5a.webp" caption="Figure 1: HIV notifications by jurisdiction, 2013 – 2022">
        <description>A dual-axis line chart tracking HIV notifications by jurisdiction (QLD, NSW, VIC, WA) and nationally from 2013 to 2022. The left vertical axis measures the number of notifications for individual jurisdictions (0–400), while the right vertical axis scales up to 1200 for the national total. Five distinct trend lines are plotted against years on the horizontal axis, showing a general decline in notifications across all categories over the decade.</description>
      </img>
    </images>
  </page>
  <page number="20">
    <text>HEPATITIS B

Age-standardised rate per 100 000
140
120
100
80
60
40
20
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Year

ACT 26.8 27.0 23.9 19.9 20.7 20.2 19.0 18.1 16.8 14.9
NT 79.2 127.7 61.9 61.9 42.8 40.5 32.7 32.5 34.3 12.2
SA 25.3 20.9 23.1 21.3 19.8 17.6 16.3 17.8 15.0 11.3
TAS 15.5 12.6 13.3 9.3 8.8 9.0 9.1 13.3 10.4 14.5
Australia 27.8 28.8 27.9 26.6 26.5 24.4 23.9 23.0 19.8 18.4

Most people living with chronic hepatitis B in Australia were born overseas and acquired hepatitis B at birth or in early childhood.

Downward trend likely related to:
• Vaccination programs being introduced in countries that many Australian migrants emigrate from
• Maternal screening and vaccination of infants born to women with Hep B

Notification rate among ATSI peoples was more than twice as high compared with the non-Indigenous population
• Reflective of higher prevalence of chronic Hep B among ATSI peoples

https://www.kirby.unsw.edu.au/sites/default/files/documents/Annual-Surveillance-Report-2022_HBV.pdf

![Source: National Notifiable Diseases Surveillance System](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_9c1b48c8fcaca742.webp)
![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_8af0a7c2f976b42e.webp)</text>
    <formatted_text>#### Hepatitis B Notifications

Age-standardised rate per 100 000 (y-axis 0–140; years 2012–2021):

| | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| ACT | 26.8 | 27.0 | 23.9 | 19.9 | 20.7 | 20.2 | 19.0 | 18.1 | 16.8 | 14.9 |
| NT | 79.2 | 127.7 | 61.9 | 61.9 | 42.8 | 40.5 | 32.7 | 32.5 | 34.3 | 12.2 |
| SA | 25.3 | 20.9 | 23.1 | 21.3 | 19.8 | 17.6 | 16.3 | 17.8 | 15.0 | 11.3 |
| TAS | 15.5 | 12.6 | 13.3 | 9.3 | 8.8 | 9.0 | 9.1 | 13.3 | 10.4 | 14.5 |
| Australia | 27.8 | 28.8 | 27.9 | 26.6 | 26.5 | 24.4 | 23.9 | 23.0 | 19.8 | 18.4 |

Most people living with chronic hepatitis B in Australia were born overseas and acquired hepatitis B at birth or in early childhood.

#### Downward Trend

Likely related to:

- Vaccination programs being introduced in countries that many Australian migrants emigrate from
- Maternal screening and vaccination of infants born to women with Hep B

#### Aboriginal and Torres Strait Islander (ATSI) Populations

Notification rate among ATSI peoples was more than twice as high compared with the non-Indigenous population:

- Reflective of higher prevalence of chronic Hep B among ATSI peoples

https://www.kirby.unsw.edu.au/sites/default/files/documents/Annual-Surveillance-Report-2022_HBV.pdf</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:15:03" confidence="6" anchor="Maternal screening and vaccination of infants born to women with Hep B">
- ==Hepatitis B vaccination for all infants in Australia was introduced around 1999–2000.==</insert>
      <insert timestamp="00:12:27" confidence="9" anchor="Reflective of higher prevalence of chronic Hep B among ATSI peoples">
- This may relate to historical vertical and early-childhood transmission before vaccination.
- Transmission through sharing among people who inject drugs is an additional risk factor.
- ==Rates are higher in the Northern Territory, reflecting the population distribution of Aboriginal and Torres Strait Islander people.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="61,365,568,642" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_9c1b48c8fcaca742.webp" caption="Source: National Notifiable Diseases Surveillance System">
        <description>A line chart showing the age-standardised notification rate per 100,000 for Hepatitis B from 2012 to 2021. The graph displays distinct trend lines for NT (Northern Territory), Australia (dashed line), ACT, SA, and TAS, highlighting a sharp peak in the NT data around 2013 followed by a general downward trajectory across all jurisdictions.</description>
      </img>
      <img order="1" bbox="64,648,563,745" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_8af0a7c2f976b42e.webp">
        <description>A data table presenting numerical values for five categories (ACT, NT, SA, TAS, and Australia) across ten columns. Each row is identified by a label with a corresponding colored square or diamond symbol on the left.</description>
      </img>
    </images>
  </page>
  <page number="21">
    <text>HEPATITIS C

Age-standardised rate per 100 000 population
120.0
100.0
80.0
60.0
40.0
20.0
0.0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 Year
NSW 43.6 46.2 45.0 44.0 58.6 50.6 58.1 42.0 36.1 30.9
QLD 52.0 53.3 54.9 53.9 58.1 48.9 43.8 47.8 43.3 41.3
VIC 37.7 37.0 36.8 36.4 39.2 30.8 29.6 25.7 20.0 19.1
WA 43.0 43.3 43.9 43.7 46.9 45.7 38.3 37.2 34.4 37.3
Australia 43.7 45.0 44.4 43.9 50.3 42.7 42.5 36.5 31.4 29.2

Uptake of hepatitis C treatment is resulting in a population level decline of hepatitis C transmission.
• In March 2016, DAA regimens became subsidised by the Pharmaceutical Benefits Scheme (PBS) for hepatitis C treatment.
• Uptake of DAA therapies was initially high but has since steeply declined.

No declines in hepatitis C notifications amongst ATSI peoples
• suggests inequity in the availability of DAAs as well as resources directed toward harm reduction.
• Hepatitis C notification rates remain several-fold higher among ATSI people compared to non-Indigenous people.

https://www.kirby.unsw.edu.au/sites/default/files/documents/Annual-Surveillance-Report-2022_HCV.pdfv

![Figure 3 Hepatitis C notification rate per 100 000 population by state/territory, 2012–2021](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_299a25ba7cf15a17.webp)
![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_dd29e4aa2c55891a.webp)</text>
    <formatted_text>#### Hepatitis C Notifications

Age-standardised rate per 100 000 population (y-axis 0–120.0; years 2012–2021):

| | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| NSW | 43.6 | 46.2 | 45.0 | 44.0 | 58.6 | 50.6 | 58.1 | 42.0 | 36.1 | 30.9 |
| QLD | 52.0 | 53.3 | 54.9 | 53.9 | 58.1 | 48.9 | 43.8 | 47.8 | 43.3 | 41.3 |
| VIC | 37.7 | 37.0 | 36.8 | 36.4 | 39.2 | 30.8 | 29.6 | 25.7 | 20.0 | 19.1 |
| WA | 43.0 | 43.3 | 43.9 | 43.7 | 46.9 | 45.7 | 38.3 | 37.2 | 34.4 | 37.3 |
| Australia | 43.7 | 45.0 | 44.4 | 43.9 | 50.3 | 42.7 | 42.5 | 36.5 | 31.4 | 29.2 |

Uptake of hepatitis C treatment is resulting in a population level decline of hepatitis C transmission.

- In March 2016, DAA regimens became subsidised by the Pharmaceutical Benefits Scheme (PBS) for hepatitis C treatment.
- Uptake of DAA therapies was initially high but has since steeply declined.

#### Aboriginal and Torres Strait Islander (ATSI) Populations

No declines in hepatitis C notifications amongst ATSI peoples:

- Suggests inequity in the availability of DAAs as well as resources directed toward harm reduction.
- Hepatitis C notification rates remain several-fold higher among ATSI people compared to non-Indigenous people.

https://www.kirby.unsw.edu.au/sites/default/files/documents/Annual-Surveillance-Report-2022_HCV.pdfv</formatted_text>
    <audio_inserts count="2">
      <insert confidence="1" anchor="Uptake of DAA therapies was initially high but has since steeply declined.">
- ==Hepatitis C treatment is now highly effective.==</insert>
      <insert timestamp="00:14:19" confidence="8" anchor="Usually takes 12–24 weeks of therapy for viral suppression below limits of detec">
- ==Single-tablet, once-daily combinations containing three antiretroviral drugs improved adherence==
- ==Newer drugs have greater potency, improved pharmacokinetic properties, less frequent dosing, fewer pills, less intolerance and less toxicity==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="43,359,542,609" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_299a25ba7cf15a17.webp" caption="Figure 3 Hepatitis C notification rate per 100 000 population by state/territory, 2012–2021">
        <description>A line chart plotting the age-standardised hepatitis C notification rate per 100,000 population over time for multiple jurisdictions. The graph displays five distinct trend lines (representing NSW, QLD, VIC, WA, and Australia) that generally fluctuate between 20 and 60, with several showing a downward trajectory towards the right side of the plot.</description>
      </img>
      <img order="1" bbox="45,614,544,737" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_dd29e4aa2c55891a.webp">
        <description>A data table presenting the age-standardised Hepatitis C notification rate per 100,000 population for NSW, QLD, VIC, WA, and Australia from 2012 to 2021.</description>
      </img>
    </images>
  </page>
  <page number="22">
    <text># TREATMENT OVER TIME</text>
  </page>
  <page number="23">
    <text>&lt;h3&gt;HIV&lt;/h3&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;b&gt;No cure&lt;/b&gt; for HIV infection&lt;/li&gt;
  &lt;li&gt;Several anti-retroviral drugs available, though costly and often associated with resistance and/or adverse reactions
    &lt;ul&gt;
      &lt;li&gt;nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse-transcriptase inhibitors (NNRTI), protease inhibitors (PI), integrase inhibitors, entry inhibitors&lt;/li&gt;
      &lt;li&gt;Multiple drugs required → high pill-burden → poor-compliance&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;Advent of specific anti-retroviral agent combinations 1996 = highly active anti-retroviral therapy (HAART)
    &lt;ul&gt;
      &lt;li&gt;Especially increased antiviral activity&lt;/li&gt;
      &lt;li&gt;Reduced pill-burden → improved compliance&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;Usually takes &lt;b&gt;&lt;i&gt;12-24 weeks of therapy for viral suppression&lt;/i&gt;&lt;/b&gt; below limits of detection&lt;/li&gt;
&lt;/ul&gt;</text>
    <formatted_text>- **No cure** for HIV infection
- Several anti-retroviral drugs available, though costly and often associated with resistance and/or adverse reactions
  - Nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse-transcriptase inhibitors (NNRTI), protease inhibitors (PI), integrase inhibitors, entry inhibitors
  - Multiple drugs required → high pill-burden → poor compliance
- Advent of specific anti-retroviral agent combinations 1996 = highly active anti-retroviral therapy (HAART)
  - Especially increased antiviral activity
  - Reduced pill-burden → improved compliance
- Usually takes **12–24 weeks of therapy for viral suppression** below limits of detection</formatted_text>
  </page>
  <page number="24">
    <text>&lt;h2&gt;HIV&lt;/h2&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;b&gt;Combination class agents:&lt;/b&gt;&lt;/li&gt;
  &lt;li&gt;Atripla = Efavirenz, emtricitabine, tenofovir&lt;/li&gt;
  &lt;li&gt;Eviplera = rilpivirine, emtricitabine, tenofovir&lt;/li&gt;
  &lt;li&gt;Stribild = elvitegravir, cobicistat, tenofovir, emtricitabine&lt;/li&gt;
  &lt;li&gt;Triumeq = abacavir, dolutegravir, lamivudine&lt;/li&gt;
  &lt;li&gt;Biktarvy = bictegravir, emtricitabine, tenofovir&lt;/li&gt;
&lt;/ul&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;td&gt;
      &lt;b&gt;Box 20.1 Main antiretroviral agents&lt;/b&gt;
      &lt;hr/&gt;
      &lt;b&gt;1. Reverse transcriptase inhibitors&lt;/b&gt;
      &lt;br/&gt;&lt;i&gt;Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)&lt;/i&gt;
      &lt;ul&gt;
        &lt;li&gt;Abacavir (ABC)&lt;/li&gt;
        &lt;li&gt;Didanosine (ddI)&lt;/li&gt;
        &lt;li&gt;Emtricitabine (FTC)&lt;/li&gt;
        &lt;li&gt;Lamivudine (3TC)&lt;/li&gt;
        &lt;li&gt;Stavudine (d4T)&lt;/li&gt;
        &lt;li&gt;Tenofovir (TDF)&lt;/li&gt;
        &lt;li&gt;Zidovudine (AZT, ZDV)&lt;/li&gt;
      &lt;/ul&gt;
      &lt;br/&gt;
      &lt;i&gt;Non-nucleotide reverse transcriptase inhibitors (NNRTIs)&lt;/i&gt;
      &lt;ul&gt;
        &lt;li&gt;Delavirdine (DLV)&lt;/li&gt;
        &lt;li&gt;Efavirenz (EFV)&lt;/li&gt;
        &lt;li&gt;Etravirine (ETR)&lt;/li&gt;
        &lt;li&gt;Nevirapine (NVP)&lt;/li&gt;
        &lt;li&gt;Rilpivirine (RPV)&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
    &lt;td&gt;
      &lt;b&gt;2. Protease inhibitors (PIs)&lt;/b&gt;
      &lt;ul&gt;
        &lt;li&gt;Atazanavir (ATV)&lt;/li&gt;
        &lt;li&gt;Darunavir (DRV)&lt;/li&gt;
        &lt;li&gt;Fosamprenavir (FPV)&lt;/li&gt;
        &lt;li&gt;Indinavir (IDV)&lt;/li&gt;
        &lt;li&gt;Lopinavir (LPV)&lt;/li&gt;
        &lt;li&gt;Nelfinavir (NFV)&lt;/li&gt;
        &lt;li&gt;Ritonavir (RTV)&lt;/li&gt;
        &lt;li&gt;Lopinavir/ritonavir (LPV/r)&lt;/li&gt;
        &lt;li&gt;Saquinavir (SQV)&lt;/li&gt;
        &lt;li&gt;Tipranavir (TPV)&lt;/li&gt;
        &lt;li&gt;Amprenavir (APV)&lt;/li&gt;
      &lt;/ul&gt;
      &lt;br/&gt;
      &lt;b&gt;3. Integrase inhibitor&lt;/b&gt;
      &lt;ul&gt;
        &lt;li&gt;Raltegravir (RAL)&lt;/li&gt;
      &lt;/ul&gt;
      &lt;br/&gt;
      &lt;b&gt;4. Entry inhibitor&lt;/b&gt;
      &lt;br/&gt;&lt;b&gt;Fusion inhibitors&lt;/b&gt;
      &lt;ul&gt;
        &lt;li&gt;Enfuvirtide (ENF, T-20)&lt;/li&gt;
      &lt;/ul&gt;
      &lt;br/&gt;
      &lt;b&gt;CCR5 antagonist&lt;/b&gt;
      &lt;ul&gt;
        &lt;li&gt;Maraviroc (MVC)&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>- **Combination class agents:**
  - Atripla = efavirenz, emtricitabine, tenofovir
  - Eviplera = rilpivirine, emtricitabine, tenofovir
  - Stribild = elvitegravir, cobicistat, tenofovir, emtricitabine
  - Triumeq = abacavir, dolutegravir, lamivudine
  - Biktarvy = bictegravir, emtricitabine, tenofovir

#### Box 20.1 Main antiretroviral agents

**1. Reverse transcriptase inhibitors**

*Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)*

- Abacavir (ABC)
- Didanosine (ddI)
- Emtricitabine (FTC)
- Lamivudine (3TC)
- Stavudine (d4T)
- Tenofovir (TDF)
- Zidovudine (AZT, ZDV)

*Non-nucleotide reverse transcriptase inhibitors (NNRTIs)*

- Delavirdine (DLV)
- Efavirenz (EFV)
- Etravirine (ETR)
- Nevirapine (NVP)
- Rilpivirine (RPV)

**2. Protease inhibitors (PIs)**

- Atazanavir (ATV)
- Darunavir (DRV)
- Fosamprenavir (FPV)
- Indinavir (IDV)
- Lopinavir (LPV)
- Nelfinavir (NFV)
- Ritonavir (RTV)
- Lopinavir/ritonavir (LPV/r)
- Saquinavir (SQV)
- Tipranavir (TPV)
- Amprenavir (APV)

**3. Integrase inhibitor**

- Raltegravir (RAL)

**4. Entry inhibitor**

*Fusion inhibitors*

- Enfuvirtide (ENF, T-20)

*CCR5 antagonist*

- Maraviroc (MVC)</formatted_text>
  </page>
  <page number="25">
    <text>HEPATITIS B

• Effective immunisation available as part of the childhood schedule

Hepatitis B screening introduced for all pregnant women. Vaccination introduced for infants born to mothers with chronic hepatitis B.

Catch-up program for 6–16 year olds introduced. A universal adolescent school-based catch-up program (11–14 years) introduced in:
• Victoria
• Tasmania

Universal infant vaccination was commenced in:
• Northern Territory

Universal adolescent school-based program introduced in:
• South Australia
• Australian Capital Territory

Hepatitis B vaccination of all infants commenced.

Universal adolescent school-based program introduced in:
• Western Australia

Universal adolescent school-based program introduced in:
• New South Wales

Universal adolescent school-based program introduced in:
• Queensland

1985 1990 1998 1999 2000 2002 2004 2007

![Figure 10 Roll-out of hepatitis B vaccination in Australia, by year](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_bf499bf44d0ef6ac.webp)</text>
    <formatted_text>- Effective immunisation available as part of the childhood schedule

#### Timeline of Hepatitis B Vaccination Programs in Australia

- **1985** – Hepatitis B screening introduced for all pregnant women. Vaccination introduced for infants born to mothers with chronic hepatitis B.
- **1990** – Catch-up program for 6–16 year olds introduced. A universal adolescent school-based catch-up program (11–14 years) introduced in:
  - Victoria
  - Tasmania
- **1998** – Universal infant vaccination commenced in:
  - Northern Territory
- **1999** – Universal adolescent school-based program introduced in:
  - South Australia
  - Australian Capital Territory
- **2000** – Hepatitis B vaccination of all infants commenced.
- **2002** – Universal adolescent school-based program introduced in:
  - Western Australia
- **2004** – Universal adolescent school-based program introduced in:
  - New South Wales
- **2007** – Universal adolescent school-based program introduced in:
  - Queensland</formatted_text>
    <images>
      <img order="0" bbox="238,445,748,801" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_bf499bf44d0ef6ac.webp" caption="Figure 10 Roll-out of hepatitis B vaccination in Australia, by year">
        <description>A horizontal timeline diagram illustrating the progressive roll-out of hepatitis B vaccination programs in Australia from 1985 to 2007. Text boxes positioned above and below the central arrow detail specific milestones, including the introduction of screening for pregnant women, catch-up programs for adolescents, and universal infant vaccination commencement across various states and territories.</description>
      </img>
    </images>
  </page>
  <page number="26">
    <text>HEPATITIS B

• BUT **no cure** for hepatitis B
  • Persists in infected hepatocytes as covalently closed circular DNA (cccDNA)
• Currently, there is no evidence of benefit to support treating everyone who lives with hepatitis B.
• Focus of acute hepatitis B: &lt;span style=&quot;color: orange;&quot;&gt;supportive care&lt;/span&gt; (e.g. rest, proper nutrition, hydration) and &lt;span style=&quot;color: orange;&quot;&gt;monitoring liver function&lt;/span&gt;
• &lt;span style=&quot;color: orange;&quot;&gt;Medications&lt;/span&gt; help an individual live well with the virus, but are not a cure.
  • Usually only need to take medications if signs of cirrhosis or ongoing liver damage (even if have chronic hepatitis B)
  • Reduce likelihood of liver disease or hepatocellular carcinoma
  • Need to be taken daily</text>
    <formatted_text>- BUT **no cure** for hepatitis B
  - Persists in infected hepatocytes as covalently closed circular DNA (cccDNA)
- Currently, there is no evidence of benefit to support treating everyone who lives with hepatitis B.
- Focus of acute hepatitis B: supportive care (e.g. rest, proper nutrition, hydration) and monitoring liver function
- Medications help an individual live well with the virus, but are not a cure.
  - Usually only need to take medications if signs of cirrhosis or ongoing liver damage (even if have chronic hepatitis B)
  - Reduce likelihood of liver disease or hepatocellular carcinoma
  - Need to be taken daily</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:15:43" confidence="5" anchor="Medications help an individual live well with the virus, but are not a cure.">
- ==People with chronic hepatitis B require monitoring for liver damage==</insert>
    </audio_inserts>
  </page>
  <page number="27">
    <text>HEPATITIS C

Non-A, non-B
(NANB) hepatitis
recognised

Only HAV and
HBV recognised

Prior to 1960s
Mid 1970s

Early 1960s

Treatment
focused on acute
illness = bed rest,
nutritious diet

Treated with
Pegylated
Interferon (PEG-
IFN) + Ribavarin
(RBV)

Significant side effects
(80% of patients)

The time course of side effects associated with
interferon

Severity

Neutropenia
Thrombocytopenia
Anemia

Flu-like
symptoms
Fatigue
Depressive/
anxiety symptoms

0 1 2 3 4 5 6 7 8 9 10 11 12
IFN treatment, weeks

Courtesy of Nezam H Afdhal, MD and T Barry Kelleher, MD, MRCPI.

![The time course of side effects associated with interferon](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_c6017be602b31279.webp)</text>
    <formatted_text>#### Historical Recognition and Treatment

- Prior to 1960s – Treatment focused on acute illness = bed rest, nutritious diet
- Early 1960s – Only HAV and HBV recognised
- Mid 1970s – Non-A, non-B (NANB) hepatitis recognised
- Treated with Pegylated Interferon (PEG-IFN) + Ribavirin (RBV)
- Significant side effects (80% of patients)

#### The Time Course of Side Effects Associated with Interferon

- Severity over IFN treatment weeks (0–12):
  - Early/throughout: flu-like symptoms, fatigue, depressive/anxiety symptoms
  - Later: neutropenia, thrombocytopenia, anemia

*Courtesy of Nezam H Afdhal, MD and T Barry Kelleher, MD, MRCPI.*</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:17:15" confidence="7" anchor="Significant side effects (80% of patients)">

&gt; [!note] Lecturer — Interferon Treatment
&gt; Interferon-based treatment had limited sustained biological effectiveness.
&gt;
&gt; - Recombinant interferon achieved a sustained biological response in approximately 6% of patients.
&gt; - Ribavirin was ineffective as monotherapy, but combining it with interferon increased the sustained response rate to approximately 34%.
&gt; - Pegylated interferon increased the sustained response rate to approximately 56% by extending the drug’s half-life through attachment of polymer chains, which reduced renal clearance.
</insert>
      <insert timestamp="00:18:10" confidence="11" anchor="Later: neutropenia, thrombocytopenia, anemia">
- ==Autoimmune disorders such as psoriasis and rheumatoid arthritis==
- ==Aggressive behaviour, hallucinations, mania and suicidal ideation==
- ==Stroke and hypothyroidism==</insert>
      <insert timestamp="00:18:57" confidence="12" anchor="2015–present – Tx for less common HCV genotypes available">

&gt; [!note] Lecturer — Direct-Acting Antivirals
&gt; Direct-acting antiviral treatment changed the course of hepatitis C therapy.
&gt;
&gt; - In 2012, protease inhibitors became available as the first direct-acting antivirals, initially only for genotype 1 and used as monotherapy.
&gt; - In 2014, interferon-free treatment became available with sofosbuvir, transforming hepatitis C treatment.
&gt; - Hepatitis C could then be cured in approximately 8–12 weeks in nearly all patients.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="174,315,441,804" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_c6017be602b31279.webp" caption="The time course of side effects associated with interferon">
        <description>A horizontal timeline diagram illustrating the historical progression of Hepatitis C recognition and treatment, with markers for 'Prior to 1960s', 'Early 1960s', and 'Mid 1970s'. Text boxes connected to the timeline detail milestones such as the initial focus on acute illness management, the recognition of HAV and HBV, the identification of Non-A, non-B (NANB) hepatitis, and modern treatment with Pegylated Interferon and Ribavirin.</description>
      </img>
    </images>
  </page>
  <page number="28">
    <text>HEPATITIS C

Events

Non-A, non-B (NANB) hepatitis recognised

Only HAV and HBV recognised
HCV isolated

Prior to 1960s
Early 1960s
Mid 1970s
1989
2012
2014-15
2015-present

Tx focused on acute illness = bed rest, nutritious diet
Pegylated Interferon (PEG-IFN) + Ribavirin (RBV)
Protease Inhibitors (telprevir, boceprevir, simeprevir)
RNA Polymerase Inhibitors (Sofosbuvir) – DAA
Tx for less common HCV genotypes available

Treatments

**Interferon-free breakthrough: 2014**

Possible to cure a severe, life-threatening chronic infection disease within 8-12 weeks in nearly all patients!

![Events Treatments](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_5035d8119e40b571.webp)</text>
    <formatted_text>#### Events and Treatments Timeline

- **Prior to 1960s** – Tx focused on acute illness = bed rest, nutritious diet
- **Early 1960s** – Only HAV and HBV recognised
- **Mid 1970s** – Non-A, non-B (NANB) hepatitis recognised
- **1989** – HCV isolated
- **2012** – Pegylated Interferon (PEG-IFN) + Ribavirin (RBV)
- **2014–15** – Protease Inhibitors (telaprevir, boceprevir, simeprevir); RNA Polymerase Inhibitors (Sofosbuvir) – DAA
- **2015–present** – Tx for less common HCV genotypes available

&gt; Interferon-free breakthrough: 2014 — possible to cure a severe, life-threatening chronic infectious disease within 8–12 weeks in nearly all patients!</formatted_text>
    <images>
      <img order="0" bbox="90,296,759,834" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_5035d8119e40b571.webp" caption="Events Treatments">
        <description>A horizontal timeline chart illustrating the historical progression of Hepatitis C milestones, with 'Events' (diagnosis and isolation) placed above the central axis and 'Treatments' placed below. The timeline spans from 'Prior to 1960s' through to '2015-present', highlighting specific medical breakthroughs like the isolation of HCV in 1989 and the introduction of DAA therapies.</description>
      </img>
    </images>
  </page>
  <page number="29">
    <text>&lt;h2&gt;HEPATITIS C&lt;/h2&gt;

*   &lt;span style=&quot;color:purple&quot;&gt;**General Management:**&lt;/span&gt;
    *   &lt;span style=&quot;color:red&quot;&gt;Lifestyle advice&lt;/span&gt; (tobacco and alcohol cessation, high CHO diet, maintaining health body weight and diet, advise on sexual transmission)
    *   &lt;span style=&quot;color:red&quot;&gt;Bed rest&lt;/span&gt;
    *   Offer hepatitis A and B &lt;span style=&quot;color:red&quot;&gt;immunisations&lt;/span&gt;
    *   &lt;span style=&quot;color:red&quot;&gt;Antiviral drugs&lt;/span&gt;
        *   Traditionally PEG-IFN and ribavirin
        *   Now include direct acting antivirals (DAAs - protease inhibitors and RNA polymerase inhibitors)
    *   &lt;span style=&quot;color:red&quot;&gt;Liver transplant&lt;/span&gt; $\rightarrow$ corticosteroid or immunosuppressive therapy</text>
    <formatted_text>**General Management:**

- Lifestyle advice (tobacco and alcohol cessation, high carbohydrate diet, maintaining healthy body weight and diet, advise on sexual transmission)
- Bed rest
- Offer hepatitis A and B immunisations
- Antiviral drugs
  - Traditionally PEG-IFN and ribavirin
  - Now include direct acting antivirals (DAAs – protease inhibitors and RNA polymerase inhibitors)
- Liver transplant → corticosteroid or immunosuppressive therapy</formatted_text>
  </page>
  <page number="30">
    <text>&lt;div style=&quot;text-align: center; font-size: 1.5em; margin-bottom: 20px; border: 2px solid black; padding: 10px;&quot;&gt;SUMMARY – TREATMENTS OVER TIME&lt;/div&gt;

&lt;table style=&quot;width: 100%; border-collapse: collapse; text-align: left; margin-top: 20px;&quot;&gt;
  &lt;thead&gt;
    &lt;tr&gt;
      &lt;th style=&quot;background-color: #8DA3B0; color: white; padding: 10px; width: 33%;&quot;&gt;HIV&lt;/th&gt;
      &lt;th style=&quot;background-color: #7CC46E; color: white; padding: 10px; width: 33%;&quot;&gt;Hep B&lt;/th&gt;
      &lt;th style=&quot;background-color: #D96C27; color: white; padding: 10px; width: 33%;&quot;&gt;Hep C&lt;/th&gt;
    &lt;/tr&gt;
  &lt;/thead&gt;
  &lt;tbody&gt;
    &lt;tr&gt;
      &lt;td style=&quot;padding: 10px; background-color: #E3E8EC;&quot;&gt;
        &lt;ul&gt;
          &lt;li&gt;Treatment provided earlier&lt;/li&gt;
          &lt;li&gt;Less side effects from treatment&lt;/li&gt;
          &lt;li&gt;Reduced pill burden &amp;rarr; increased compliance&lt;/li&gt;
          &lt;li&gt;People living well with HIV (stable, managed)&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/td&gt;
      &lt;td style=&quot;padding: 10px; background-color: #E2F0DD;&quot;&gt;
        &lt;ul&gt;
          &lt;li&gt;Fewer people diagnosed due to childhood immunisation schedule&lt;/li&gt;
          &lt;li&gt;Not much progress with treatment options&lt;/li&gt;
          &lt;li&gt;No cure&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/td&gt;
      &lt;td style=&quot;padding: 10px; background-color: #FCE4E1;&quot;&gt;
        &lt;ul&gt;
          &lt;li&gt;Much improved side-effect profile from treatment&lt;/li&gt;
          &lt;li&gt;Only 2-3 months of treatment (c.f. 6-12 months)&lt;/li&gt;
          &lt;li&gt;Aim of treatment: achieve SVR (sustained virologic response)&lt;/li&gt;
          &lt;li&gt;Good success rate of HCV cure&lt;/li&gt;
        &lt;/ul&gt;
      &lt;/td&gt;
    &lt;/tr&gt;
  &lt;/tbody&gt;
&lt;/table&gt;</text>
    <formatted_text>| HIV | Hep B | Hep C |
|---|---|---|
| - Treatment provided earlier&lt;br&gt;- Less side effects from treatment&lt;br&gt;- Reduced pill burden → increased compliance&lt;br&gt;- People living well with HIV (stable, managed) | - Fewer people diagnosed due to childhood immunisation schedule&lt;br&gt;- Not much progress with treatment options&lt;br&gt;- No cure | - Much improved side-effect profile from treatment&lt;br&gt;- Only 2–3 months of treatment (c.f. 6–12 months)&lt;br&gt;- Aim of treatment: achieve SVR (sustained virologic response)&lt;br&gt;- Good success rate of HCV cure |</formatted_text>
    <audio_inserts count="9">
      <insert timestamp="00:20:07" confidence="4" anchor="- People living well with HIV (stable, managed)">
- ==Oral manifestations previously associated with poorly controlled HIV are seen less often==</insert>
      <insert timestamp="00:37:41" confidence="2" anchor="Many HIV-infected individuals continue to have concerns about privacy Stigma and">
- ==HIV status should not be written on clinic day sheets or other materials that may be visible to others.==</insert>
      <insert timestamp="00:24:09" confidence="10" anchor="Maintain medical confidentiality Increased risk of opportunistic infections (e.g">

&gt; [!note] Lecturer — HIV Consent
&gt; Information must not be provided to relatives without the patient's consent. HIV-associated neurocognitive disorders may affect the ability to consent in later stages of HIV progression.
</insert>
      <insert timestamp="00:24:43" confidence="11" anchor="Post-operative: Caution prescribing — drug interactions with antiviral medicatio">

&gt; [!note] Lecturer — HIV Surgery
&gt; Advanced immunosuppression may increase the risks of infection and poor wound healing. Specialist referral may be appropriate for urgent dental care in significantly immunocompromised patients; HIV transmission risk is reduced when viral load is suppressed, and post-exposure prophylaxis is available following relevant exposure.
</insert>
      <insert timestamp="00:27:17" confidence="9" anchor="Sialosis, sialadenitis, hyposalivation, sicca syndrome Chronic/untreated Hep C: ">
- ==Reduced salivary flow may be due to direct viral effects or other causes.==</insert>
      <insert timestamp="00:27:52" confidence="3" anchor="If known to be incubating hepatitis, active clinical hepatitis, or in convalesce">
- ==Emergency care may be provided where appropriate.==</insert>
      <insert timestamp="00:28:25" confidence="3" anchor="Hepatic encephalopathy: advanced cirrhosis Preventive dental care important with">
- ==Liver function, bleeding risk and medication safety should be discussed with the relevant medical team.==</insert>
      <insert timestamp="00:28:56" confidence="4" anchor="Check for jaundice or deranged LFTs — avoid elective dental treatment, consult p">

&gt; [!note] Lecturer — Liver Disease
&gt; Lidocaine was described as being metabolised by the liver, whereas articaine was described as being metabolised in blood plasma. Articaine was therefore presented as the preferred local anaesthetic option in liver disease.
</insert>
      <insert timestamp="00:30:55" confidence="6" anchor="Post-operative: Caution hepatotoxic drugs #### Spread - See upcoming slides — st">
- ==Safe handling and disposal of needles and medical waste are essential.==</insert>
    </audio_inserts>
  </page>
  <page number="31">
    <text/>
  </page>
  <page number="32">
    <text>HIV – ORAL MANIFESTATIONS

Leao JC, Ribeiro CM,
Carvalho AA, Frezzini
C, Porter S. Oral
Complications of HIV
Disease. Clinics.
2009;64:459-70

| Group 1 lesions strongly associated with HIV infection | Group 2 lesions less commonly associated with HIV infection | Group 3 lesions seen in HIV infection |
| :--- | :--- | :--- |
| **Candidosis**&lt;br&gt;• Erythematous&lt;br&gt;• Pseudomembranous | **Bacterial infections**&lt;br&gt;• Mycobacterium avium-intracellulare&lt;br&gt;• Mycobacterium tuberculosis | **Bacterial infections**&lt;br&gt;• Actinomyces israelii&lt;br&gt;• Escherichia coli&lt;br&gt;• Klebsiella pneumonia |
| **Hairy leukoplakia** | **Melanotic hyperpigmentation** | **Cat-scratch disease** |
| **Kaposi’s sarcoma** | **Necrotizing (ulcerative) stomatitis (Figure 5)** | **Drug-reactions**&lt;br&gt;• Ulcerative&lt;br&gt;• erythema multiforme&lt;br&gt;• lichenoid&lt;br&gt;• toxic epidermolysis |
| **Non-Hodgkin’s lymphoma** | **Salivary gland diseases**&lt;br&gt;• Dry mouth due to decreased salivary flow rate&lt;br&gt;• Unilateral or bilateral swelling of major salivary glands | **Epithelioid (bacillary) angiomatosis** |
| **Periodontal disease**&lt;br&gt;• Linear gingival erythema&lt;br&gt;• Necrotizing gingivitis&lt;br&gt;• Necrotizing periodontitis | **Thrombocytopenic purpura** | **Fungal infections other than candida**&lt;br&gt;• Cryptococcus neoformans&lt;br&gt;• Geotrichum candidum&lt;br&gt;• Histoplasma capsulatum&lt;br&gt;• Mucoraceae (mucormycosis, zygomycosis)&lt;br&gt;• Aspergillus flavus |
| | **Ulceration NOS (not otherwise specified)** | **Neurological disturbances**&lt;br&gt;• Facial palsy&lt;br&gt;• Trigeminal neuralgia |
| | **Viral infections**&lt;br&gt;• Herpes simplex virus&lt;br&gt;• Human papillomavirus lesions&lt;br&gt;◆ Condyloma acuminatum&lt;br&gt;◆ Focal epithelial hyperplasia&lt;br&gt;◆ Verruca vulgaris&lt;br&gt;• Varicella zoster virus&lt;br&gt;◆ Herpes zoster&lt;br&gt;◆ Varicella | **Viral infections**&lt;br&gt;• Cytomegalovirus&lt;br&gt;• Molluscum contagiosum |

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_90bb3a6850caab61.webp)</text>
    <formatted_text>*Leao JC, Ribeiro CM, Carvalho AA, Frezzini C, Porter S. Oral Complications of HIV Disease. Clinics. 2009;64:459-70.*

#### Group 1: Lesions Strongly Associated with HIV Infection

- **Candidosis**
  - Erythematous
  - Pseudomembranous
- **Hairy leukoplakia**
- **Kaposi's sarcoma**
- **Non-Hodgkin's lymphoma**
- **Periodontal disease**
  - Linear gingival erythema
  - Necrotizing gingivitis
  - Necrotizing periodontitis

#### Group 2: Lesions Less Commonly Associated with HIV Infection

- **Bacterial infections**
  - Mycobacterium avium-intracellulare
  - Mycobacterium tuberculosis
- **Melanotic hyperpigmentation**
- **Necrotizing (ulcerative) stomatitis** (Figure 5)
- **Salivary gland diseases**
  - Dry mouth due to decreased salivary flow rate
  - Unilateral or bilateral swelling of major salivary glands
- **Thrombocytopenic purpura**
- **Ulceration NOS** (not otherwise specified)
- **Viral infections**
  - Herpes simplex virus
  - Human papillomavirus lesions
    - Condyloma acuminatum
    - Focal epithelial hyperplasia
    - Verruca vulgaris
  - Varicella zoster virus
    - Herpes zoster
    - Varicella

#### Group 3: Lesions Seen in HIV Infection

- **Bacterial infections**
  - Actinomyces israelii
  - Escherichia coli
  - Klebsiella pneumonia
- **Cat-scratch disease**
- **Drug reactions**
  - Ulcerative
  - Erythema multiforme
  - Lichenoid
  - Toxic epidermolysis
- **Epithelioid (bacillary) angiomatosis**
- **Fungal infections other than Candida**
  - Cryptococcus neoformans
  - Geotrichum candidum
  - Histoplasma capsulatum
  - Mucoraceae (mucormycosis, zygomycosis)
  - Aspergillus flavus
- **Neurological disturbances**
  - Facial palsy
  - Trigeminal neuralgia
- **Viral infections**
  - Cytomegalovirus
  - Molluscum contagiosum</formatted_text>
    <images>
      <img order="0" bbox="193,279,809,842" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_90bb3a6850caab61.webp">
        <description>A three-column table categorizing oral manifestations of HIV infection into Group 1 (lesions strongly associated), Group 2 (lesions less commonly associated), and Group 3 (lesions seen in HIV infection). The columns list specific conditions such as Candidosis, Hairy leukoplakia, Kaposi's sarcoma, bacterial infections, salivary gland diseases, and drug-reactions.</description>
      </img>
    </images>
  </page>
  <page number="33">
    <text>HIV – ORAL MANIFESTATIONS

Leao JC, Ribeiro CM, Carvalho AA, Frezzini C, Porter S. Oral Complications of HIV Disease. Clinics. 2009;64:459-70

![Figure 1 - Severe pseudomembranous candidosis (Thrush) in HIV disease](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_bca0db5e9e60ca44.webp)
![Figure 2 - Oral hairy leukoplakia – this finding can also be a feature of iatrogenic immunosuppression](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_91e18d6c4c7c47cf.webp)
![Figure 3 - Kaposi’s sarcoma of the right buccal vestibule in an undiagnosed HIV-infected patient](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_4d9ded98ac576565.webp)
![Figure 4 - Necrotizing gingivitis in HIV disease](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_498784b758b02654.webp)
![Figure 5 - Necrotic oral mucosal ulceration, possibly associated with CMV in severe HIV disease](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_0159463061610a7a.webp)</text>
    <formatted_text>*Leao JC, Ribeiro CM, Carvalho AA, Frezzini C, Porter S. Oral Complications of HIV Disease. Clinics. 2009;64:459-70.*</formatted_text>
    <images>
      <img order="0" bbox="115,287,368,513" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_bca0db5e9e60ca44.webp" caption="Figure 1 - Severe pseudomembranous candidosis (Thrush) in HIV disease">
        <description>Clinical photo: An intraoral close-up showing the dorsal surface of a tongue heavily coated with thick, white, curd-like plaques characteristic of pseudomembranous candidosis (thrush). The lesions are confluent across the anterior and mid-tongue, interspersed with areas of erythematous (red) mucosa where the plaque is thinner or absent.</description>
      </img>
      <img order="1" bbox="404,285,638,510" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_91e18d6c4c7c47cf.webp" caption="Figure 2 - Oral hairy leukoplakia – this finding can also be a feature of iatrogenic immunosuppression">
        <description>Clinical photo: An intraoral view of the lateral border of a tongue, showing characteristic corrugated, white, non-scrapable plaques consistent with oral hairy leukoplakia.</description>
      </img>
      <img order="2" bbox="717,285,941,509" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_4d9ded98ac576565.webp" caption="Figure 3 - Kaposi’s sarcoma of the right buccal vestibule in an undiagnosed HIV-infected patient">
        <description>Clinical photo showing a large, dark purple-red nodular lesion on the buccal mucosa adjacent to the teeth. The mass appears raised and distinct from the surrounding pink tissue, illustrating a manifestation of Kaposi's sarcoma.</description>
      </img>
      <img order="3" bbox="140,568,321,836" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_498784b758b02654.webp" caption="Figure 4 - Necrotizing gingivitis in HIV disease">
        <description>Clinical photo: A close-up view of the gingival margin along posterior teeth, showing erythematous (red) and swollen gum tissue with a distinct white/yellowish pseudomembrane or slough covering the interdental papillae and marginal gingiva.</description>
      </img>
      <img order="4" bbox="436,566,628,811" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_0159463061610a7a.webp" caption="Figure 5 - Necrotic oral mucosal ulceration, possibly associated with CMV in severe HIV disease">
        <description>Clinical photo: An intraoral view showing the posterior mandibular teeth and surrounding gingiva, with a dental mirror visible on the right side. The image illustrates severe periodontal destruction, including deep ulceration of the interdental papilla, necrotic sloughing of tissue, and significant gum recession exposing the tooth roots.</description>
      </img>
    </images>
  </page>
  <page number="34">
    <text>HIV – MEDICATION SIDE EFFECTS

| Oral side effect | Class of drug | Name of drug |
| :--- | :--- | :--- |
| **Erythema multiforme** | NRTIs | *Zidovudine (ZVD)Abacavir (ABC)Didanosine (DDI)Zalcitabine* |
| | NNRTIs | *EfavirenzDelaviridineNevirapineSaquinavir* |
| **Hyperpigmentation** | NRTIs | *Zidovudine (ZVD)* |
| **Lipodystrophy** | NRTIs | *Stavudine* |
| | PIs | *SaquinavirRitonavir* |
| **Xerostomia** | NRTIs | *Lamivudine (3TC)Didanosine* |
| | PIs | *SaquinavirIndinavirNelfinavirRitonavir* |
| **Parotid lipomatosis** | PIs | *IndinavirRitonavirSaquinavirNelfinavirAt* |
| **Cheilitis** | PI | *Indinavir* |
| **Perioral paresthesia** | PIs | *RitonavirAmprenavir* |
| **Taste disturbances** | PIs | *IndinabirRitonavir* |
| **Facial edema** | PIs | *Ritonavir* |
| **Ulcers** | NRTIs | *AbacavirZalcitabineNevirapine* |
| **Lip enlargement** | EIs | *Enfuvirtide* |

**NRTI** = nucleoside analog reverse transcriptase inhibitors; **NNRTI** = non-nucleoside analog reverse transcriptase inhibitors; **PIs** = protease inhibitors; **EI** = entry inhibitors

Leao JC, Ribeiro CM, Carvalho AA, Frezzini C, Porter S. Oral Complications of HIV Disease. Clinics. 2009;64:459-70

![Oral and systemic side effects of antiretroviral drugs (ARDs)](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_79dfe9915afbe07c.webp)</text>
    <formatted_text>| Oral side effect | Class of drug | Name of drug |
| :--- | :--- | :--- |
| Erythema multiforme | NRTIs | Zidovudine (ZVD), Abacavir (ABC), Didanosine (DDI), Zalcitabine |
| | NNRTIs | Efavirenz, Delavirdine, Nevirapine, Saquinavir |
| Hyperpigmentation | NRTIs | Zidovudine (ZVD) |
| Lipodystrophy | NRTIs | Stavudine |
| | PIs | Saquinavir, Ritonavir |
| Xerostomia | NRTIs | Lamivudine (3TC), Didanosine |
| | PIs | Saquinavir, Indinavir, Nelfinavir, Ritonavir |
| Parotid lipomatosis | PIs | Indinavir, Ritonavir, Saquinavir, Nelfinavir |
| Cheilitis | PI | Indinavir |
| Perioral paresthesia | PIs | Ritonavir, Amprenavir |
| Taste disturbances | PIs | Indinavir, Ritonavir |
| Facial edema | PIs | Ritonavir |
| Ulcers | NRTIs | Abacavir, Zalcitabine, Nevirapine |
| Lip enlargement | EIs | Enfuvirtide |

**NRTI** = nucleoside analog reverse transcriptase inhibitors; **NNRTI** = non-nucleoside analog reverse transcriptase inhibitors; **PIs** = protease inhibitors; **EI** = entry inhibitors

*Leao JC, Ribeiro CM, Carvalho AA, Frezzini C, Porter S. Oral Complications of HIV Disease. Clinics. 2009;64:459-70.*</formatted_text>
    <images>
      <img order="0" bbox="230,329,768,697" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_79dfe9915afbe07c.webp" caption="Oral and systemic side effects of antiretroviral drugs (ARDs)">
        <description>A three-column table listing oral side effects, the class of drug responsible, and specific names of antiretroviral drugs. The columns are titled 'Oral side effect', 'Class of drug', and 'Name of drug', with entries including conditions like erythema multiforme, hyperpigmentation, xerostomia, and parotid lipomatosis.</description>
      </img>
    </images>
  </page>
  <page number="35">
    <text>&lt;div align=&quot;center&quot;&gt;&lt;b&gt;HIV&lt;/b&gt;&lt;/div&gt;

&lt;br&gt;

**ORAL FEATURES**

*   Uncommon in well-managed and stable patients
*   Perioral paraesthesia
    *   Rare adverse reacti
*   Increased risk of oral disease (immunocompromise)
    *   Opportunistic infections
    *   Periodontal disease
    *   Oral hairy leukoplakia
    *   Oral cancer
    *   HIV-related salivary gland hypofunction

**DENTAL IMPLICATIONS**

*   Immunocompromised:
    *   Caution with proceed with dental treatment if
*   Antiretroviral drug interactions
    *   Many commonly prescribed drugs (e.g. benzodiazepines can reach high levels toxicity)
    *   Consult HIV specialist before prescribing drugs
*   Spread
    *   Standard precautions
    *   Needlestick injury policy</text>
    <formatted_text>#### Oral Features

- Uncommon in well-managed and stable patients
- Perioral paraesthesia (rare adverse reaction)
- Increased risk of oral disease (immunocompromise)
  - Opportunistic infections
  - Periodontal disease
  - Oral hairy leukoplakia
  - Oral cancer
  - HIV-related salivary gland hypofunction

#### Dental Implications

- **Immunocompromised:** caution with proceeding with dental treatment
- **Antiretroviral drug interactions**
  - Many commonly prescribed drugs (e.g. benzodiazepines can reach high levels of toxicity)
  - Consult HIV specialist before prescribing drugs
- **Spread**
  - Standard precautions
  - Needlestick injury policy</formatted_text>
  </page>
  <page number="36">
    <text>&lt;div align=&quot;center&quot;&gt;&lt;b&gt;HIV&lt;/b&gt;&lt;/div&gt;

*   **ACCESS:**
    *   Safe, non-judgemental, empathetic environment
    *   Many HIV-infected individuals continue to have concerns about privacy.
    *   Stigma and social implications of their infection may prevent them from accessing general dental services

*   **COMMUNICATION / CONSENT / EDUCATION:**
    *   Maintain medical confidentiality
    *   Increased risk of opportunistic infections (e.g. oral thrush), periodontal disease, cancer (Kaposi sarcoma / NHL) $\rightarrow$ preventive advice, routine recalls
    *   HIV-associated neurocognitive disorders (HAND)</text>
    <formatted_text>#### Access

- Safe, non-judgemental, empathetic environment
- Many HIV-infected individuals continue to have concerns about privacy
- Stigma and social implications of their infection may prevent them from accessing general dental services

#### Communication / Consent / Education

- Maintain medical confidentiality
- Increased risk of opportunistic infections (e.g. oral thrush), periodontal disease, cancer (Kaposi sarcoma / NHL) → preventive advice, routine recalls
- HIV-associated neurocognitive disorders (HAND)</formatted_text>
  </page>
  <page number="37">
    <text>&lt;h2&gt;HIV&lt;/h2&gt;

*   **SURGERY**
    *   **Pre-operative:** understand disease control
        *   Immunocompromised: CD4 &amp;lt;200 cells/mm³, absolute neutrophil count &amp;lt;1x10⁹/L
            *   Trend is more important than any single count
            *   CD4% can be a more stable indication of whether there has been a change in the immune system (12-15% is equivalent to 200 cells/mm³)
            *   ?surgical antibiotic prophylaxis
        *   Viral load: if compliant with treatment, should be undetectable
        *   Platelet count
    *   **Peri-operative:**
        *   Some antiviral drugs can enhance benzodiazepine activity
    *   **Post-operative:**
        *   caution prescribing – drug interactions with antiviral medications

*   **SPREAD**
    *   See upcoming slides – standard precautions</text>
    <formatted_text>#### Surgery

- **Pre-operative:** understand disease control
  - Immunocompromised: CD4 &lt; 200 cells/mm³, absolute neutrophil count &lt; 1 x 10⁹/L
    - Trend is more important than any single count
    - CD4% can be a more stable indication of whether there has been a change in the immune system (12–15% is equivalent to 200 cells/mm³)
    - ?surgical antibiotic prophylaxis
  - Viral load: if compliant with treatment, should be undetectable
  - Platelet count
- **Peri-operative:**
  - Some antiviral drugs can enhance benzodiazepine activity
- **Post-operative:**
  - Caution prescribing — drug interactions with antiviral medications

#### Spread

- See upcoming slides — standard precautions</formatted_text>
  </page>
  <page number="38">
    <text>&lt;h2&gt;HEPATITIS B&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th style=&quot;width: 50%;&quot;&gt;ORAL FEATURES&lt;/th&gt;
    &lt;th style=&quot;width: 50%;&quot;&gt;DENTAL IMPLICATIONS&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Possible gingival bleeding, petechiae, ecchymoses&lt;/li&gt;
        &lt;li&gt;Icteric patients: Discolouration of posterior palate and FoM along lingual fraenum&lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
    &lt;td&gt;
      &lt;ul&gt;
        &lt;li&gt;Liver cirrhosis $\rightarrow$ liver failure (see GIT Hepatology lecture)
          &lt;ul&gt;
            &lt;li&gt;Profound immune compromise associated with end-stage cirrhosis&lt;/li&gt;
            &lt;li&gt;Hepatic encephalopathy&lt;/li&gt;
          &lt;/ul&gt;
        &lt;/li&gt;
        &lt;li&gt;Bleeding risk (see Bleeding Disorders lecture)&lt;/li&gt;
        &lt;li&gt;Drug metabolism
          &lt;ul&gt;
            &lt;li&gt;Dosage&lt;/li&gt;
            &lt;li&gt;Hepatotoxic drugs (avoid sedatives, NSAIDs ; do not exceed max dose of paracetamol)&lt;/li&gt;
          &lt;/ul&gt;
        &lt;/li&gt;
        &lt;li&gt;Spread
          &lt;ul&gt;
            &lt;li&gt;Standard precautions&lt;/li&gt;
            &lt;li&gt;Needlestick injury policy&lt;/li&gt;
          &lt;/ul&gt;
        &lt;/li&gt;
      &lt;/ul&gt;
    &lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>#### Oral Features

- Possible gingival bleeding, petechiae, ecchymoses
- Icteric patients: discolouration of posterior palate and floor of mouth along lingual fraenum

#### Dental Implications

- Liver cirrhosis → liver failure (see GIT Hepatology lecture)
  - Profound immune compromise associated with end-stage cirrhosis
  - Hepatic encephalopathy
- Bleeding risk (see Bleeding Disorders lecture)
- Drug metabolism
  - Dosage
  - Hepatotoxic drugs (avoid sedatives, NSAIDs; do not exceed max dose of paracetamol)
- Spread
  - Standard precautions
  - Needlestick injury policy</formatted_text>
  </page>
  <page number="39">
    <text>&lt;h2&gt;HEPATITIS C&lt;/h2&gt;

&lt;h3&gt;ORAL FEATURES&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Possible gingival bleeding, petechiae, ecchymoses&lt;/li&gt;
&lt;li&gt;Icterics patients: Discolouration of posterior palate and FoM along lingual fraenum&lt;/li&gt;
&lt;li&gt;Sialosis, sialadenitis, hyposalivation, sicca syndrome&lt;/li&gt;
&lt;li&gt;Chronic/untreated Hep C: Association with NHL, lichen planus, periodontal disease&lt;/li&gt;
&lt;/ul&gt;

&lt;h3&gt;DENTAL IMPLICATIONS&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;Liver cirrhosis &amp;rarr; liver failure (see &lt;i&gt;GIT Hepatology lecture&lt;/i&gt;)&lt;/li&gt;
&lt;li&gt;Profound immune compromise associated with end-stage cirrhosis&lt;/li&gt;
&lt;li&gt;Hepatic encephalopathy&lt;/li&gt;
&lt;li&gt;Bleeding risk (see &lt;i&gt;Bleeding Disorders lecture&lt;/i&gt;)&lt;/li&gt;
&lt;li&gt;Drug metabolism&lt;/li&gt;
&lt;li&gt;Dosage&lt;/li&gt;
&lt;li&gt;Hepatotoxic drugs (avoid sedatives, NSAIDs ; do not exceed max dose of paracetamol)&lt;/li&gt;
&lt;li&gt;Spread&lt;/li&gt;
&lt;li&gt;Standard precautions&lt;/li&gt;
&lt;li&gt;Needlestick injury policy&lt;/li&gt;
&lt;/ul&gt;</text>
    <formatted_text>#### Oral Features

- Possible gingival bleeding, petechiae, ecchymoses
- Icteric patients: discolouration of posterior palate and floor of mouth along lingual fraenum
- Sialosis, sialadenitis, hyposalivation, sicca syndrome
- Chronic/untreated Hep C: association with NHL, lichen planus, periodontal disease

#### Dental Implications

- Liver cirrhosis → liver failure (see *GIT Hepatology lecture*)
- Profound immune compromise associated with end-stage cirrhosis
- Hepatic encephalopathy
- Bleeding risk (see *Bleeding Disorders lecture*)
- Drug metabolism
  - Dosage
  - Hepatotoxic drugs (avoid sedatives, NSAIDs; do not exceed max dose of paracetamol)
- Spread
  - Standard precautions
  - Needlestick injury policy</formatted_text>
  </page>
  <page number="40">
    <text># VIRAL HEPATITIS

*   **ACCESS:**
    *   if known to be incubating hepatitis, active clinical hepatitis, or in convalescent stages $\rightarrow$ defer elective dental treatment where possible until recovery.
    *   Incubation/acute phase: hospital environment, emergency care only
    *   Decompensated liver disease: hospital environment, emergency care only

*   **COMMUNICATION / CONSENT / EDUCATION:**
    *   Hepatic encephalopathy: advanced cirrhosis
    *   Preventive dental care important with Hep C due to reduced salivary flow (outcome of major restorative treatment may be poor)</text>
    <formatted_text>#### Access

- If known to be incubating hepatitis, active clinical hepatitis, or in convalescent stages → defer elective dental treatment where possible until recovery
- Incubation/acute phase: hospital environment, emergency care only
- Decompensated liver disease: hospital environment, emergency care only

#### Communication / Consent / Education

- Hepatic encephalopathy: advanced cirrhosis
- Preventive dental care important with Hep C due to reduced salivary flow (outcome of major restorative treatment may be poor)</formatted_text>
  </page>
  <page number="41">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
VIRAL HEPATITIS
&lt;/div&gt;

*   SURGICAL
    *   Pre-operative:
        *   check for jaundice or deranged LFTs – avoid elective dental treatment, consult physician
        *   Prothrombin time test and platelet counts
        *   ?surgical antibiotic prophylaxis if end-stage cirrhosis (profound immunocompromise)
    *   Peri-operative:
        *   LA: minimise lignocaine, ideally articaine
        *   CS: caution benzodiazepines
    *   Post-operative
        *   Caution hepatotoxic drugs

*   SPREAD
    *   See upcoming slides – standard precautions</text>
    <formatted_text>#### Surgical Considerations

- **Pre-operative:**
  - Check for jaundice or deranged LFTs — avoid elective dental treatment, consult physician
  - Prothrombin time test and platelet counts
  - ?surgical antibiotic prophylaxis if end-stage cirrhosis (profound immunocompromise)
- **Peri-operative:**
  - LA: minimise lignocaine, ideally articaine
  - CS: caution benzodiazepines
- **Post-operative:**
  - Caution hepatotoxic drugs

#### Spread

- See upcoming slides — standard precautions</formatted_text>
  </page>
  <page number="42">
    <text/>
  </page>
  <page number="43">
    <text>RISK OF TRANSMISSION RATES

*   **Hep B** = 1:3
    *   positive source to an unvaccinated individual
*   **Hep C** = 1:30 (2008)
    *   likely less now with effective HCV therapy (closer to 1:200 to 1:50)
    *   Range of transmission risk is 0-10% (average 1.8-1.9%)
*   **HIV** = 1:300 (2014)
    *   likely less now with ART and PEP

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_27954aa7e5c2f4c2.webp)</text>
    <formatted_text>- **Hep B** = 1:3
  - Positive source to an unvaccinated individual
- **Hep C** = 1:30 (2008)
  - Likely less now with effective HCV therapy (closer to 1:200 to 1:50)
  - Range of transmission risk is 0-10% (average 1.8-1.9%)
- **HIV** = 1:300 (2014)
  - Likely less now with ART and PEP</formatted_text>
    <images>
      <img order="0" bbox="651,467,921,704" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_27954aa7e5c2f4c2.webp">
        <description>A close-up photograph showing a gloved hand holding a finger that has been pricked by a needle, with a visible drop of blood on the fingertip.</description>
      </img>
    </images>
  </page>
  <page number="44">
    <text>## PREVENTION

| HIV | Hep B | Hep C |
| :--- | :--- | :--- |
| • No vaccine available&lt;br&gt;• PrEP | • Childhood immunisation schedule | • No vaccine available |</text>
    <formatted_text>| HIV | Hep B | Hep C |
| :--- | :--- | :--- |
| - No vaccine available&lt;br&gt;- PrEP | - Childhood immunisation schedule | - No vaccine available |</formatted_text>
  </page>
  <page number="45">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;h1&gt;PREVENTION&lt;/h1&gt;
&lt;/div&gt;

* safe and appropriate use of health-care injections and procedures;
* safe handling and disposal of needles and medical waste;
* harm-reduction services for people who inject drugs, such as needle exchange programmes, substance use counselling
* testing of donated blood for the BBVs
* practicing safe sex by using barrier methods such as condoms.

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_9b8909ce1a1a5fa6.webp)</text>
    <formatted_text>- Safe and appropriate use of health-care injections and procedures
- Safe handling and disposal of needles and medical waste
- Harm-reduction services for people who inject drugs, such as needle exchange programmes, substance use counselling
- Testing of donated blood for the BBVs
- Practicing safe sex by using barrier methods such as condoms</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:10:50" confidence="3" anchor="Practicing safe sex by using barrier methods such as condoms">
- ==HIV testing, treatment and prophylaxis==</insert>
      <insert timestamp="00:32:09" confidence="5" anchor="**Daily use of antiretroviral medications by HIV-negative individuals at increas">
    - ==PrEP can substantially reduce the risk of contracting HIV==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="701,453,972,689" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_9b8909ce1a1a5fa6.webp">
        <description>A clinical photograph showing several used syringes with attached needles arranged next to a red sharps container. The container is prominently labelled 'DANGER' and features a biohazard symbol, illustrating the safe handling and disposal of medical waste.</description>
      </img>
    </images>
  </page>
  <page number="46">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
&lt;h3&gt;HIV&lt;/h3&gt;
&lt;/div&gt;

*   **&lt;span style=&quot;color: orange;&quot;&gt;PrEP = Pre-Exposure Prophylaxis&lt;/span&gt;**
    *   Daily use of antiretroviral medications by HIV-negative individuals at increased risk of HIV exposure
*   PrEP should be considered for all people at risk of HIV, including:
    *   Gay, bisexual and men who have sex with men
    *   Trans and gender diverse populations
    *   Heterosexuals who may have sex with people at a higher risk of HIV, or have partners with an unknown HIV status
    *   People who inject drugs
    *   People who have arrived from overseas country with high-prevalence of HIV, who may not be connected to health services</text>
    <formatted_text>- **PrEP = Pre-Exposure Prophylaxis**
  - Daily use of antiretroviral medications by HIV-negative individuals at increased risk of HIV exposure
- PrEP should be considered for all people at risk of HIV, including:
  - Gay, bisexual and men who have sex with men
  - Trans and gender diverse populations
  - Heterosexuals who may have sex with people at a higher risk of HIV, or have partners with an unknown HIV status
  - People who inject drugs
  - People who have arrived from overseas country with high-prevalence of HIV, who may not be connected to health services</formatted_text>
  </page>
  <page number="47">
    <text>&lt;h1&gt;HEPATITIS B&lt;/h1&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;3&quot;&gt;Table 1. Serological tests that constitute the diagnostic panel for HBV&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Hepatitis B surface antigen&lt;/td&gt;
    &lt;td&gt;Active infection (acute or chronic)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Hepatitis B surface antibody&lt;/td&gt;
    &lt;td&gt;Immunity (vaccination or infection)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Hepatitis B core antibody&lt;/td&gt;
    &lt;td&gt;Infection (past or current)&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;4&quot;&gt;Table 2. Interpretation of HBV serology&lt;sup&gt;3&lt;/sup&gt;&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;Susceptible (consider vaccination)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;Resolved HBV infection&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;Vaccinated&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;Acute HBV infection*&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;IgM anti-HBc* (high titre)&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;Chronic HBV infection*&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;IgM anti-HBc*&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;HBsAg&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;Various possibilities (see 'What if the result is inconclusive?')&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBc&lt;/td&gt;
    &lt;td&gt;Positive&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Anti-HBs&lt;/td&gt;
    &lt;td&gt;Negative&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td colspan=&quot;4&quot;&gt;&lt;em&gt;*&lt;/em&gt; Anti-HBc IgM can also be present (usually at a lower titre) in a flare of CHB&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![Table 1. Serological tests that constitute the diagnostic panel for HBV](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_71ea382ed61cf388.webp)
![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_c6e237da3f9d4dfb.webp)
![Table 2. Interpretation of HBV serology3](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_ac48ff8f27a83e69.webp)</text>
    <formatted_text>**Table 1. Serological tests that constitute the diagnostic panel for HBV**

| Test | Name | Meaning |
| :--- | :--- | :--- |
| HBsAg | Hepatitis B surface antigen | Active infection (acute or chronic) |
| Anti-HBs | Hepatitis B surface antibody | Immunity (vaccination or infection) |
| Anti-HBc | Hepatitis B core antibody | Infection (past or current) |

**Table 2. Interpretation of HBV serology³**

| Tests | Result | Interpretation |
| :--- | :--- | :--- |
| HBsAg, Anti-HBc, Anti-HBs | All negative | Susceptible (consider vaccination) |
| HBsAg negative; Anti-HBc positive; Anti-HBs positive | — | Resolved HBV infection |
| HBsAg negative; Anti-HBc negative; Anti-HBs positive | — | Vaccinated |
| HBsAg positive; Anti-HBc positive; IgM anti-HBc* (high titre) positive; Anti-HBs negative | — | Acute HBV infection* |
| HBsAg positive; Anti-HBc positive; IgM anti-HBc* negative; Anti-HBs negative | — | Chronic HBV infection* |
| HBsAg negative; Anti-HBc positive; Anti-HBs negative | — | Various possibilities (see 'What if the result is inconclusive?') |

\* Anti-HBc IgM can also be present (usually at a lower titre) in a flare of CHB</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:32:49" confidence="6" anchor="HBsAg negative; Anti-HBc positive; Anti-HBs negative | — | Various possibilities">

&gt; [!note] Lecturer — Serology Interpretation
&gt; Interpreting the three hepatitis B serological results helps categorise individuals accurately.
&gt;
&gt; - This can help avoid misdiagnosis, unnecessary recalls, additional testing and unnecessary vaccination.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="40,368,539,496" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_71ea382ed61cf388.webp" caption="Table 1. Serological tests that constitute the diagnostic panel for HBV">
        <description>Table: Serological tests that constitute the diagnostic panel for HBV. It lists three markers (HBsAg, Anti-HBs, and Anti-HBc) with their full names and what a positive result indicates regarding infection status or immunity.</description>
      </img>
      <img order="1" bbox="137,543,405,799" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_c6e237da3f9d4dfb.webp">
        <description>A photograph showing a healthcare worker in teal scrubs handing a purple booklet titled 'all about me!' to a crying infant who is being held by an adult.</description>
      </img>
      <img order="2" bbox="576,286,966,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_ac48ff8f27a83e69.webp" caption="Table 2. Interpretation of HBV serology3">
        <description>Table: A reference chart titled 'Interpretation of HBV serology' that correlates specific patterns of positive and negative results for Hepatitis B surface antigen (HBsAg), core antibody (Anti-HBc), and surface antibody (Anti-HBs) with clinical diagnoses such as susceptibility, resolved infection, vaccination status, acute or chronic infection, and inconclusive possibilities.</description>
      </img>
    </images>
  </page>
  <page number="48">
    <text/>
  </page>
  <page number="49">
    <text>AHPRA REGISTRATION AND
RENEWAL

**Exposure Prone Procedures**

Before answering these questions, you need to read the Board’s Guidelines – Registered health practitioners and students in relation to blood borne viruses. You can access them from the Ahpra renewal page (https://www.ahpra.gov.au/Registration/Renewal.aspx).

These guidelines are for practitioners and students who perform exposure-prone procedures and require you to comply with the Communicable Diseases Network Australia (CDNA) guidelines *Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses* (https://www.health.gov.au/resources/collections/cdna-national-guidelines-for-healthcare-workers-on-managing-bloodbornviruses) This includes **testing for HIV, Hepatitis C and Hepatitis B at least every three years.**

Exposure-prone procedures (EPPs) are procedures where there is a risk of injury to the healthcare worker resulting in exposure of the patient’s open tissues to the blood of the healthcare worker. These procedures include those where the healthcare worker’s hands (whether gloved or not) may be in contact with sharp instruments, needle tips or sharp tissues (spicules of bone or teeth) inside a patient’s open body cavity, wound or confined anatomical space where the hands or fingertips may not be completely visible at all times.

*(required) Do you perform exposure-prone procedures?*
Yes No

* (required) During the preceding period of registration, have you complied with the Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses?
Yes No

* (required) If your registration is renewed, do you intend to perform exposure-prone procedures?
Yes No

* (required) If your registration is renewed, do you commit to comply with the Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses?
Yes No

If your circumstances change during the upcoming period of registration and you are no longer able to comply with the CDNA guidelines, you need to stop performing exposure prone procedures.

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_698119fc05d44515.webp)</text>
    <formatted_text>#### Exposure Prone Procedures

Before answering these questions, you need to read the Board's Guidelines – Registered health practitioners and students in relation to blood borne viruses. You can access them from the Ahpra renewal page (https://www.ahpra.gov.au/Registration/Renewal.aspx).

These guidelines are for practitioners and students who perform exposure-prone procedures and require you to comply with the Communicable Diseases Network Australia (CDNA) guidelines *Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses* (https://www.health.gov.au/resources/collections/cdna-national-guidelines-for-healthcare-workers-on-managing-bloodbornviruses). This includes **testing for HIV, Hepatitis C and Hepatitis B at least every three years.**

Exposure-prone procedures (EPPs) are procedures where there is a risk of injury to the healthcare worker resulting in exposure of the patient's open tissues to the blood of the healthcare worker. These procedures include those where the healthcare worker's hands (whether gloved or not) may be in contact with sharp instruments, needle tips or sharp tissues (spicules of bone or teeth) inside a patient's open body cavity, wound or confined anatomical space where the hands or fingertips may not be completely visible at all times.

#### Ahpra Renewal Questions

- *(required)* Do you perform exposure-prone procedures? — Yes / No
- *(required)* During the preceding period of registration, have you complied with the Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses? — Yes / No
- *(required)* If your registration is renewed, do you intend to perform exposure-prone procedures? — Yes / No
- *(required)* If your registration is renewed, do you commit to comply with the Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses? — Yes / No

&gt; If your circumstances change during the upcoming period of registration and you are no longer able to comply with the CDNA guidelines, you need to stop performing exposure prone procedures.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:33:21" confidence="8" anchor="These guidelines are for practitioners and students who perform exposure-prone p">
- ==Dentists must renew registration with the Australian Health Practitioner Regulation Agency each year.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="579,668,630,688" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_698119fc05d44515.webp">
        <description>The crop displays a horizontal pair of rectangular buttons or selection fields labeled 'Yes' and 'No'. This interface element corresponds to the binary choice options for the required questions regarding exposure-prone procedures listed on the slide.</description>
      </img>
    </images>
  </page>
  <page number="50">
    <text>**CDNA NATIONAL GUIDELINES FOR HEALTHCARE WORKERS 2018**

These Guidelines provide information and recommendations for all healthcare workers (HCWs), in particular:
o HCWs who perform exposure prone procedures (EPPs)
o HCWs living with a blood borne virus (BBV)
o doctors treating HCWs with a BBV

Communicable Diseases network AUSTRALIA

**AUSTRALIAN NATIONAL GUIDELINES FOR THE MANAGEMENT OF HEALTHCARE WORKERS LIVING WITH BLOOD BORNE VIRUSES AND HEALTHCARE WORKERS WHO PERFORM EXPOSURE PRONE PROCEDURES AT RISK OF EXPOSURE TO BLOOD BORNE VIRUSES**</text>
    <formatted_text>These Guidelines provide information and recommendations for all healthcare workers (HCWs), in particular:

- HCWs who perform exposure prone procedures (EPPs)
- HCWs living with a blood borne virus (BBV)
- doctors treating HCWs with a BBV

*Communicable Diseases Network Australia*

*Australian national guidelines for the management of healthcare workers living with blood borne viruses and healthcare workers who perform exposure prone procedures at risk of exposure to blood borne viruses*</formatted_text>
  </page>
  <page number="51">
    <text>RISKS OF TRANSMISSION BETWEEN
HCW AND PATIENT

| Blood Borne Virus | Risk of infected HCW to patient transmission | Risk of infected patient to HCW transmission |
| :--- | :--- | :--- |
| Hepatitis B virus | 0.2% - 13.19% | 1% - 62%* |
| Hepatitis C virus | 0.04% - 4.35% | 0% - 7% |
| Human immunodeficiency virus | 0.0000024% - 0.000024% | 0.3% |

* There is a wide variability in infectiousness of people with hepatitis B reported in the literature and this depends on their hepatitis B e-antigen status.

![Table 1: Risk of BBV transmission per exposure episode from untreated infected HCW to patient and untreated infected patient to HCW (in the absence of additional risk management).](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_df77fab6948bd8b7.webp)</text>
    <formatted_text>| Blood Borne Virus | Risk of infected HCW to patient transmission | Risk of infected patient to HCW transmission |
| :--- | :--- | :--- |
| Hepatitis B virus | 0.2% - 13.19% | 1% - 62%* |
| Hepatitis C virus | 0.04% - 4.35% | 0% - 7% |
| Human immunodeficiency virus | 0.0000024% - 0.000024% | 0.3% |

\* There is a wide variability in infectiousness of people with hepatitis B reported in the literature and this depends on their hepatitis B e-antigen status.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:35:12" confidence="16" anchor="* There is a wide variability in infectiousness of people with hepatitis B repor">

&gt; [!note] Lecturer — Hepatitis B Transmission
&gt; Hepatitis B is the most readily transmitted bloodborne virus and may be transmitted without visible blood.
&gt;
&gt; - Transmission can occur through percutaneous exposure, mucosal exposure, or non-intact skin, including eczema, burns and wounds.
&gt; - Published cases documented at least 55 healthcare workers transmitting hepatitis B to more than 500 patients after testing became available in the 1970s.
&gt; - Transmission decreased after standard or universal infection-prevention precautions were introduced.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="219,517,775,698" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_df77fab6948bd8b7.webp" caption="Table 1: Risk of BBV transmission per exposure episode from untreated infected HCW to patient and untreated infected patient to HCW (in the absence of additional risk management).">
        <description>A table listing the percentage risks of blood-borne virus transmission per exposure episode between healthcare workers and patients, detailing specific ranges for Hepatitis B, C, and HIV.</description>
      </img>
    </images>
  </page>
  <page number="52">
    <text>CDNA NATIONAL GUIDELINES FOR
HEALTHCARE WORKERS 2018

*   **All healthcare workers:**
    *   should be encouraged to undertake regular testing for blood borne viruses
    *   have the right to access confidential testing, counselling, support and treatment
    *   should be vaccinated against hepatitis B virus.</text>
    <formatted_text>- **All healthcare workers:**
  - should be encouraged to undertake regular testing for blood borne viruses
  - have the right to access confidential testing, counselling, support and treatment
  - should be vaccinated against hepatitis B virus.</formatted_text>
  </page>
  <page number="53">
    <text>&lt;div style=&quot;border: 2px solid black; padding: 10px; text-align: center; margin-bottom: 20px;&quot;&gt;
CDNA NATIONAL GUIDELINES FOR
HEALTHCARE WORKERS 2018
&lt;/div&gt;

*   **Healthcare workers living with a blood borne virus:**
    *   must have appropriate and ongoing medical care
    *   must be tested for the respective blood borne virus viral load levels, as well as for other blood borne viruses, in accordance with the National Guidelines
    *   must comply with the listed blood borne virus criteria in the National Guidelines</text>
    <formatted_text>- **Healthcare workers living with a blood borne virus:**
  - must have appropriate and ongoing medical care
  - must be tested for the respective blood borne virus viral load levels, as well as for other blood borne viruses, in accordance with the National Guidelines
  - must comply with the listed blood borne virus criteria in the National Guidelines</formatted_text>
  </page>
  <page number="54">
    <text>EXPOSURE PRONE PROCEDURES

The National Guidelines define exposure prone procedures as:

“procedures where there is a risk of injury to the healthcare worker resulting in exposure of the patient’s open tissues to the blood of the healthcare worker. These procedures include those where the healthcare worker’s hands (whether gloved or not) may be in contact with sharp instruments, needle tips or sharp tissues (spicules of bone or teeth) inside a patient’s open body cavity, wound or confined anatomical space where the hands or fingertips may not be completely visible at all times.”

**Operative dentistry!**

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_9c01d61a980d68b7.webp)</text>
    <formatted_text>The National Guidelines define exposure prone procedures as:

&gt; &quot;procedures where there is a risk of injury to the healthcare worker resulting in exposure of the patient's open tissues to the blood of the healthcare worker. These procedures include those where the healthcare worker's hands (whether gloved or not) may be in contact with sharp instruments, needle tips or sharp tissues (spicules of bone or teeth) inside a patient's open body cavity, wound or confined anatomical space where the hands or fingertips may not be completely visible at all times.&quot;

**Operative dentistry!**</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:36:30" confidence="11" anchor="The National Guidelines define exposure prone procedures as:">

&gt; [!note] Lecturer — EPP Eligibility
&gt; From July 2020, healthcare workers living with bloodborne viruses were permitted to perform exposure-prone procedures again, provided they complied with the updated CDNA requirements. Previously, healthcare workers living with HIV, hepatitis B or hepatitis C were prohibited from performing exposure-prone procedures.
</insert>
      <insert timestamp="00:37:41" confidence="4" anchor="These procedures include those where the healthcare worker's hands (whether glov">

&gt; [!note] Lecturer — Dental EPPs
&gt; Dentistry generally involves exposure-prone procedures. Most dental procedures, apart from examinations and possibly radiographs, may meet the definition because the operator’s fingers may not be visible at all times in the patient’s mouth.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="758,633,959,815" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_9c01d61a980d68b7.webp">
        <description>A clinical photograph showing a close-up view of a dental procedure on a patient's open mouth. A gloved hand is positioned near the teeth while a metal instrument, resembling pliers or forceps, is held above the upper jaw.</description>
      </img>
    </images>
  </page>
  <page number="55">
    <text>&lt;div style=&quot;text-align: center; border: 2px solid black; padding: 10px; margin-bottom: 20px;&quot;&gt;
CDNA NATIONAL GUIDELINES FOR&lt;br&gt;
HEALTHCARE WORKERS 2018
&lt;/div&gt;

*   **Healthcare workers who perform exposure prone procedures:**
    *   must take reasonable steps to know their blood borne virus status and should be tested for blood borne viruses at least once every 3 years
    *   must declare when applying for renewal of registration that they are complying with, and have been tested in accordance with the National Guidelines
    *   should understand their obligation to report their blood borne virus status, if required, under jurisdictional legislation and/or policies
    *   should understand their obligation to report all sharps injuries, whether or not there was a risk of patient exposure</text>
    <formatted_text>- **Healthcare workers who perform exposure prone procedures:**
  - must take reasonable steps to know their blood borne virus status and should be tested for blood borne viruses at least once every 3 years
  - must declare when applying for renewal of registration that they are complying with, and have been tested in accordance with, the National Guidelines
  - should understand their obligation to report their blood borne virus status, if required, under jurisdictional legislation and/or policies
  - should understand their obligation to report all sharps injuries, whether or not there was a risk of patient exposure</formatted_text>
  </page>
  <page number="56">
    <text>BBV TESTING REQUIREMENTS FOR
HCW’S WHO PERFORM EPP’S

HCW who
performs EPPs

Tested for BBVs

Tests positive for
HBV

Stops performing
EPPs
immediately

If under care of
specialist and
viral load
&lt;200IU/mL

Resume EPPs
(re-tested every
6 months if on
treatment, 3
months if not on
treatment)

Tests positive for
HCV

Stops performing
EPPs
immediately

If under care of
specialist, HCV
RNA negative (if
not treated) or
SVR (if treated)

Resume EPPs
(re-tested for
BBVs according
to guidelines)

Tests positive for
HIV

Stops performing
EPPs
immediately

If under care of
specialist, on
effective cART
and viral load
&lt;200 copies/mL
(or elite
controller)

Resume EPPs
(re-tested every 3
months)

Tests negative for
BBVs

Continues to
perform EPPs

Re-tested for
BBVs according
to guidelines

SVR: Sustained virological response, cART: combination antiretroviral therapy

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_51b405d6acde9276.webp)</text>
    <formatted_text>#### HCW Who Performs EPPs – Testing Pathways

- **Tested for BBVs → tests negative**
  - Continues to perform EPPs
  - Re-tested for BBVs according to guidelines

- **Tests positive for HBV → stops performing EPPs immediately**
  - If under care of specialist and viral load &lt;200 IU/mL → resumes EPPs (re-tested every 6 months if on treatment, 3 months if not on treatment)

- **Tests positive for HCV → stops performing EPPs immediately**
  - If under care of specialist, HCV RNA negative (if not treated) or SVR (if treated) → resumes EPPs (re-tested for BBVs according to guidelines)

- **Tests positive for HIV → stops performing EPPs immediately**
  - If under care of specialist, on effective cART and viral load &lt;200 copies/mL (or elite controller) → resumes EPPs (re-tested every 3 months)

*SVR: Sustained virological response, cART: combination antiretroviral therapy*</formatted_text>
    <images>
      <img order="0" bbox="188,342,815,694" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_51b405d6acde9276.webp">
        <description>A flowchart illustrating the testing and management requirements for healthcare workers (HCWs) who perform exposure-prone procedures (EPPs). The diagram branches based on test results for Hepatitis B (green), Hepatitis C (blue), HIV (red), or negative results (black), detailing immediate cessation of EPPs upon positive results and specific viral load or treatment criteria required to resume performing them.</description>
      </img>
    </images>
  </page>
  <page number="57">
    <text>QUESTIONS?

Jeeyun.leung@uwa.edu.au

![](L10 HIV HepC HepB - DMD3 DENT5311_figures/img_f4d0c671f54b60a5.webp)</text>
    <formatted_text>Questions? Contact: Jeeyun.leung@uwa.edu.au</formatted_text>
    <audio_inserts count="1">
      <insert confidence="1" anchor="Questions? Contact: Jeeyun.leung@uwa.edu.au">

&gt; [!note] Lecturer — Questions
&gt; The lecture concluded with an invitation for questions and an offer to remain available afterwards for additional questions.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="538,307,962,714" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L10 HIV HepC HepB - DMD3 DENT5311_figures/img_f4d0c671f54b60a5.webp">
        <description>A collage of six clinical and laboratory images arranged around a central white question mark icon. The surrounding panels depict microscopic fungal elements (likely yeast cells), a patient lying in a hospital bed, a child holding their chest, a red eye showing signs of inflammation, a foot stepping on a nail, and gloved hands holding an agar plate with clear zones of inhibition.</description>
      </img>
    </images>
  </page>
  <page number="58">
    <text>&lt;div style=&quot;border: 2px solid black; padding: 10px; text-align: center; width: fit-content; margin: 0 auto;&quot;&gt;
&lt;b&gt;RESOURCES&lt;/b&gt;
&lt;/div&gt;

*   Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) = &lt;a href=&quot;https://ashm.org.au/&quot;&gt;https://ashm.org.au/&lt;/a&gt;

*   Kirby Institute UNSW = &lt;a href=&quot;https://www.kirby.unsw.edu.au/&quot;&gt;https://www.kirby.unsw.edu.au/&lt;/a&gt;

*   CDNA National Guidelines for healthcare workers on managing bloodborne viruses = &lt;a href=&quot;https://www.cdc.gov.au/resources/collections/cdna-national-guidelines-healthcare-workers-bbv&quot;&gt;https://www.cdc.gov.au/resources/collections/cdna-national-guidelines-healthcare-workers-bbv&lt;/a&gt;</text>
    <formatted_text>#### Resources

- Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM): https://ashm.org.au/
- Kirby Institute UNSW: https://www.kirby.unsw.edu.au/
- CDNA National Guidelines for healthcare workers on managing bloodborne viruses: https://www.cdc.gov.au/resources/collections/cdna-national-guidelines-healthcare-workers-bbv</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:10:31" confidence="12" anchor="- CDNA National Guidelines for healthcare workers on managing bloodborne viruses">
- ==The Kirby Institute at the University of New South Wales coordinates national surveillance and reporting for HIV, viral hepatitis and sexually transmissible infections in Australia.==
- ==Follow local needlestick-injury and bloodborne-virus policies.==</insert>
    </audio_inserts>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=1|L10 HIV HepC HepB - DMD3 DENT5311, p.1]]
[^2]: Original PDF page 2: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=2|L10 HIV HepC HepB - DMD3 DENT5311, p.2]]
[^3]: Original PDF page 3: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=3|L10 HIV HepC HepB - DMD3 DENT5311, p.3]]
[^4]: Original PDF page 4: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=4|L10 HIV HepC HepB - DMD3 DENT5311, p.4]]
[^5]: Original PDF page 5: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=5|L10 HIV HepC HepB - DMD3 DENT5311, p.5]]
[^6]: Original PDF page 6: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=6|L10 HIV HepC HepB - DMD3 DENT5311, p.6]]
[^7]: Original PDF page 7: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=7|L10 HIV HepC HepB - DMD3 DENT5311, p.7]]
[^8]: Original PDF page 8: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=8|L10 HIV HepC HepB - DMD3 DENT5311, p.8]]
[^9]: Original PDF page 9: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=9|L10 HIV HepC HepB - DMD3 DENT5311, p.9]]
[^10]: Original PDF page 10: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=10|L10 HIV HepC HepB - DMD3 DENT5311, p.10]]
[^11]: Original PDF page 11: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=11|L10 HIV HepC HepB - DMD3 DENT5311, p.11]]
[^12]: Original PDF page 12: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=12|L10 HIV HepC HepB - DMD3 DENT5311, p.12]]
[^13]: Original PDF page 13: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=13|L10 HIV HepC HepB - DMD3 DENT5311, p.13]]
[^14]: Original PDF page 14: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=14|L10 HIV HepC HepB - DMD3 DENT5311, p.14]]
[^15]: Original PDF page 15: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=15|L10 HIV HepC HepB - DMD3 DENT5311, p.15]]
[^16]: Original PDF page 16: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=16|L10 HIV HepC HepB - DMD3 DENT5311, p.16]]
[^17]: Original PDF page 17: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=17|L10 HIV HepC HepB - DMD3 DENT5311, p.17]]
[^18]: Original PDF page 18: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=18|L10 HIV HepC HepB - DMD3 DENT5311, p.18]]
[^19]: Original PDF page 19: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=19|L10 HIV HepC HepB - DMD3 DENT5311, p.19]]
[^20]: Original PDF page 20: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=20|L10 HIV HepC HepB - DMD3 DENT5311, p.20]]
[^21]: Original PDF page 21: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=21|L10 HIV HepC HepB - DMD3 DENT5311, p.21]]
[^22]: Original PDF page 22: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=22|L10 HIV HepC HepB - DMD3 DENT5311, p.22]]
[^23]: Original PDF page 23: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=23|L10 HIV HepC HepB - DMD3 DENT5311, p.23]]
[^24]: Original PDF page 24: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=24|L10 HIV HepC HepB - DMD3 DENT5311, p.24]]
[^25]: Original PDF page 25: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=25|L10 HIV HepC HepB - DMD3 DENT5311, p.25]]
[^26]: Original PDF page 26: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=26|L10 HIV HepC HepB - DMD3 DENT5311, p.26]]
[^27]: Original PDF page 27: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=27|L10 HIV HepC HepB - DMD3 DENT5311, p.27]]
[^28]: Original PDF page 28: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=28|L10 HIV HepC HepB - DMD3 DENT5311, p.28]]
[^29]: Original PDF page 29: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=29|L10 HIV HepC HepB - DMD3 DENT5311, p.29]]
[^30]: Original PDF page 30: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=30|L10 HIV HepC HepB - DMD3 DENT5311, p.30]]
[^31]: Original PDF page 31: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=31|L10 HIV HepC HepB - DMD3 DENT5311, p.31]]
[^32]: Original PDF page 32: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=32|L10 HIV HepC HepB - DMD3 DENT5311, p.32]]
[^33]: Original PDF page 33: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=33|L10 HIV HepC HepB - DMD3 DENT5311, p.33]]
[^34]: Original PDF page 34: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=34|L10 HIV HepC HepB - DMD3 DENT5311, p.34]]
[^35]: Original PDF page 35: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=35|L10 HIV HepC HepB - DMD3 DENT5311, p.35]]
[^36]: Original PDF page 36: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=36|L10 HIV HepC HepB - DMD3 DENT5311, p.36]]
[^37]: Original PDF page 37: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=37|L10 HIV HepC HepB - DMD3 DENT5311, p.37]]
[^38]: Original PDF page 38: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=38|L10 HIV HepC HepB - DMD3 DENT5311, p.38]]
[^39]: Original PDF page 39: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=39|L10 HIV HepC HepB - DMD3 DENT5311, p.39]]
[^40]: Original PDF page 40: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=40|L10 HIV HepC HepB - DMD3 DENT5311, p.40]]
[^41]: Original PDF page 41: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=41|L10 HIV HepC HepB - DMD3 DENT5311, p.41]]
[^42]: Original PDF page 42: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=42|L10 HIV HepC HepB - DMD3 DENT5311, p.42]]
[^43]: Original PDF page 43: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=43|L10 HIV HepC HepB - DMD3 DENT5311, p.43]]
[^44]: Original PDF page 44: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=44|L10 HIV HepC HepB - DMD3 DENT5311, p.44]]
[^45]: Original PDF page 45: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=45|L10 HIV HepC HepB - DMD3 DENT5311, p.45]]
[^46]: Original PDF page 46: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=46|L10 HIV HepC HepB - DMD3 DENT5311, p.46]]
[^47]: Original PDF page 47: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=47|L10 HIV HepC HepB - DMD3 DENT5311, p.47]]
[^48]: Original PDF page 48: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=48|L10 HIV HepC HepB - DMD3 DENT5311, p.48]]
[^49]: Original PDF page 49: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=49|L10 HIV HepC HepB - DMD3 DENT5311, p.49]]
[^50]: Original PDF page 50: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=50|L10 HIV HepC HepB - DMD3 DENT5311, p.50]]
[^51]: Original PDF page 51: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=51|L10 HIV HepC HepB - DMD3 DENT5311, p.51]]
[^52]: Original PDF page 52: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=52|L10 HIV HepC HepB - DMD3 DENT5311, p.52]]
[^53]: Original PDF page 53: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=53|L10 HIV HepC HepB - DMD3 DENT5311, p.53]]
[^54]: Original PDF page 54: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=54|L10 HIV HepC HepB - DMD3 DENT5311, p.54]]
[^55]: Original PDF page 55: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=55|L10 HIV HepC HepB - DMD3 DENT5311, p.55]]
[^56]: Original PDF page 56: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=56|L10 HIV HepC HepB - DMD3 DENT5311, p.56]]
[^57]: Original PDF page 57: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=57|L10 HIV HepC HepB - DMD3 DENT5311, p.57]]
[^58]: Original PDF page 58: [[L10 HIV HepC HepB - DMD3 DENT5311.pdf#page=58|L10 HIV HepC HepB - DMD3 DENT5311, p.58]]</footnotes>
</document>
